Medicinal Chemistry, Pharmacology, and Potential Therapeutic Benefits of Cannabinoid CB2Receptor Agonists

Chemical Reviews

Volumn 116, Issue 2, 2016, Pages 519-560

  Aghazadeh Tabrizi, Mojgan ^a   Baraldi, Pier Giovanni ^a   Borea, Pier Andrea ^a   Varani, Katia ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMISTRY;

MEDICINAL CHEMISTRY; MOLECULAR CHARACTERIZATION; SIGNAL TRANSDUCTION PATHWAYS; STRUCTURE AND ACTIVITIES; THERAPEUTIC BENEFITS;

SIGNAL TRANSDUCTION;

CANNABINOID; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; NONSTEROID ANTIINFLAMMATORY AGENT;

AGONISTS; ANIMAL; CHEMISTRY; HUMAN; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CANNABINOIDS; ENDOCANNABINOIDS; HUMANS; RECEPTOR, CANNABINOID, CB2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84955575404     PISSN: 00092665     EISSN: 15206890     Source Type: Journal    
DOI: 10.1021/acs.chemrev.5b00411     Document Type: Review

References (321)

1. Di Marzo, V.; Bifulco, M.; De Petrocellis, L. The Endocannabinoid System and Its Therapeutic Exploitation Nat. Rev. Drug Discovery 2004, 3 (9) 771-784 10.1038/nrd1495
2. Ahn, K.; McKinney, M. K.; Cravatt, B. F. Enzymatic Pathways That Regulate Endocannabinoid Signaling in the Nervous System Chem. Rev. 2008, 108 (5) 1687-1707 10.1021/cr0782067
3. Di Marzo, V.; Bisogno, T.; De Petrocellis, L. Endocannabinoids and Related Compounds: Walking Back and Forth between Plant Natural Products and Animal Physiology Chem. Biol. 2007, 14 (7) 741-756 10.1016/j.chembiol.2007.05.014
4. Di Iorio, G.; Lupi, M.; Sarchione, F.; Matarazzo, I.; Santacroce, R.; Petruccelli, F.; Martinotti, G.; Di Giannantonio, M. The Endocannabinoid System: A Putative Role in Neurodegenerative Diseases Int. J. high risk Behav. Addict. 2013, 2 (3) 100-106 10.5812/ijhrba.9222
5. Makriyannis, A. 2012 Division of Medicinal Chemistry Award Address. Trekking the Cannabinoid Road: A Personal Perspective J. Med. Chem. 2014, 57 (10) 3891-3911 10.1021/jm500220s
6. Howlett, A. C.; Barth, F.; Bonner, T. I.; Cabral, G.; Casellas, P.; Devane, W. A.; Felder, C. C.; Herkenham, M.; Mackie, K.; Martin, B. R. et al. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors Pharmacol. Rev. 2002, 54 (2) 161-202 10.1124/pr.54.2.161
7. Piomelli, D. The Molecular Logic of Endocannabinoid Signalling Nat. Rev. Neurosci. 2003, 4 (11) 873-884 10.1038/nrn1247
8. Whiteside, G. T.; Lee, G. P.; Valenzano, K. J. The Role of the Cannabinoid CB2 Receptor in Pain Transmission and Therapeutic Potential of Small Molecule CB2 Receptor Agonists Curr. Med. Chem. 2007, 14 (8) 917-936 10.2174/092986707780363023
9. Malfitano, A. M.; Basu, S.; Maresz, K.; Bifulco, M.; Dittel, B. N. What We Know and Do Not Know about the Cannabinoid Receptor 2 (CB2) Semin. Immunol. 2014, 26 (5) 369-379 10.1016/j.smim.2014.04.002
10. Pertwee, R. G. Targeting the Endocannabinoid System with Cannabinoid Receptor Agonists: Pharmacological Strategies and Therapeutic Possibilities Philos. Trans. R. Soc., B 2012, 367 (1607) 3353-3363 10.1098/rstb.2011.0381
11. Picone, R. P.; Kendall, D. A. Minireview: From the Bench, toward the Clinic: Therapeutic Opportunities for Cannabinoid Receptor Modulation Mol. Endocrinol. 2015, 29 (6) 801-813 10.1210/me.2015-1062
12. Nevalainen, T. Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands Curr. Med. Chem. 2014, 21 (2) 187-203 10.2174/09298673113206660296
13. Vemuri, V. K.; Makriyannis, A. Medicinal Chemistry of Cannabinoids Clin. Pharmacol. Ther. 2015, 97 (6) 553-558 10.1002/cpt.115
14. Baraldi, P. G.; Saponaro, G.; Moorman, A. R.; Romagnoli, R.; Preti, D.; Baraldi, S.; Ruggiero, E.; Varani, K.; Targa, M.; Vincenzi, F. et al. 7-Oxo-[1,4]oxazino[2,3,4-Ij]quinoline-6-Carboxamides as Selective CB(2) Cannabinoid Receptor Ligands: Structural Investigations around a Novel Class of Full Agonists J. Med. Chem. 2012, 55 (14) 6608-6623 10.1021/jm300763w
15. Aghazadeh Tabrizi, M.; Baraldi, P. G.; Saponaro, G.; Moorman, A. R.; Romagnoli, R.; Preti, D.; Baraldi, S.; Corciulo, C.; Vincenzi, F.; Borea, P. A. et al. Design, Synthesis, and Pharmacological Properties of New Heteroarylpyridine/heteroarylpyrimidine Derivatives as CB(2) Cannabinoid Receptor Partial Agonists J. Med. Chem. 2013, 56 (3) 1098-1112 10.1021/jm301527r
16. Aghazadeh Tabrizi, M.; Baraldi, P. G.; Saponaro, G.; Moorman, A. R.; Romagnoli, R.; Preti, D.; Baraldi, S.; Ruggiero, E.; Tintori, C.; Tuccinardi, T. et al. Discovery of 7-oxopyrazolo[1,5-A]pyrimidine-6-Carboxamides as Potent and Selective CB(2) Cannabinoid Receptor Inverse Agonists J. Med. Chem. 2013, 56 (11) 4482-4496 10.1021/jm400182t
17. Onaivi, E. S.; Leonard, C. M.; Ishiguro, H.; Zhang, P. W.; Lin, Z.; Akinshola, B. E.; Uhl, G. R. Endocannabinoids and Cannabinoid Receptor Genetics Prog. Neurobiol. 2002, 66 (5) 307-344 10.1016/S0301-0082(02)00007-2
18. Turcotte, C.; Chouinard, F.; Lefebvre, J. S.; Flamand, N. Regulation of Inflammation by Cannabinoids, the Endocannabinoids 2-Arachidonoyl-Glycerol and Arachidonoyl-Ethanolamide, and Their Metabolites J. Leukocyte Biol. 2015, 97 (6) 1049-1070 10.1189/jlb.3RU0115-021R
19. Fratta, W.; Fattore, L. Molecular Mechanisms of Cannabinoid Addiction Curr. Opin. Neurobiol. 2013, 23 (4) 487-492 10.1016/j.conb.2013.02.002
20. Pertwee, R. G.; Ross, R. A. Cannabinoid Receptors and Their Ligands Prostaglandins, Leukotrienes Essent. Fatty Acids 2002, 66 (2-3) 101-121 10.1054/plef.2001.0341
21. Davies, S. N.; Pertwee, R. G.; Riedel, G. Functions of Cannabinoid Receptors in the Hippocampus Neuropharmacology 2002, 42 (8) 993-1007 10.1016/S0028-3908(02)00060-6
22. 2Pharmacol. Rev. 2010, 62 (4) 588-631 10.1124/pr.110.003004
23. Howlett, A. C.; Barth, F.; Bonner, T. I.; Cabral, G.; Casellas, P.; Devane, W. A.; Felder, C. C.; Herkenham, M.; Mackie, K.; Martin, B. R. et al. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors Pharmacol. Rev. 2002, 54 (2) 161-202 10.1124/pr.54.2.161
24. Griffin, G.; Tao, Q.; Abood, M. E. Cloning and Pharmacological Characterization of the Rat CB(2) Cannabinoid Receptor J. Pharmacol. Exp. Ther. 2000, 292 (3) 886-894
25. Feng, W.; Song, Z. H. Functional Roles of the Tyrosine within the NP(X)(n)Y Motif and the Cysteines in the C-Terminal Juxtamembrane Region of the CB2 Cannabinoid Receptor FEBS Lett. 2001, 501 (2-3) 166-170 10.1016/S0014-5793(01)02642-4
26. Reggio, P. H. Cannabinoid Receptors and Their Ligands: Ligand-Ligand and Ligand-Receptor Modeling Approaches. Handbook of Experimental Pharmacology; Springer-Verlag: Berlin/Heidelberg, 2005; Vol. 168, pp 247-281.
27. Liu, Q.-R.; Pan, C.-H.; Hishimoto, A.; Li, C.-Y.; Xi, Z.-X.; Llorente-Berzal, A.; Viveros, M.-P.; Ishiguro, H.; Arinami, T.; Onaivi, E. S. et al. Species Differences in Cannabinoid Receptor 2 (CNR2 Gene): Identification of Novel Human and Rodent CB2 Isoforms, Differential Tissue Expression and Regulation by Cannabinoid Receptor Ligands Genes, Brain Behav. 2009, 8 (5) 519-530 10.1111/j.1601-183X.2009.00498.x
28. Howlett, A. C.; Breivogel, C. S.; Childers, S. R.; Deadwyler, S. A.; Hampson, R. E.; Porrino, L. J. Cannabinoid Physiology and Pharmacology: 30 Years of Progress Neuropharmacology 2004, 47 (Suppl 1) 345-358 10.1016/j.neuropharm.2004.07.030
29. Howlett, A. C. The Cannabinoid Receptors Prostaglandins Other Lipid Mediators 2002, 68-69, 619-631 10.1016/S0090-6980(02)00060-6
30. Dalton, G. D.; Bass, C. E.; Van Horn, C. G.; Howlett, A. C. Signal Transduction via Cannabinoid Receptors CNS Neurol. Disord.: Drug Targets 2009, 8 (6) 422-431 10.2174/187152709789824615
31. Thompson, M. D.; Cole, D. E. C.; Capra, V.; Siminovitch, K. A.; Rovati, G. E.; Burnham, W. M.; Rana, B. K. Pharmacogenetics of the G Protein-Coupled Receptors Methods Mol. Biol. 2014, 1175, 189-242 10.1007/978-1-4939-0956-8
32. Birdsall, N. J. M. Class A GPCR Heterodimers: Evidence from Binding Studies Trends Pharmacol. Sci. 2010, 31 (11) 499-508 10.1016/j.tips.2010.08.003
33. Perrey, D. A.; Gilmour, B. P.; Thomas, B. F.; Zhang, Y. Toward the Development of Bivalent Ligand Probes of Cannabinoid CB1 and Orexin OX1 Receptor Heterodimers ACS Med. Chem. Lett. 2014, 5 (6) 634-638 10.1021/ml4004759
34. 1Receptor Complexes Eur. J. Pharmacol. 2013, 721 (1-3) 341-354 10.1016/j.ejphar.2013.09.002
35. Bauer, M.; Chicca, A.; Tamborrini, M.; Eisen, D.; Lerner, R.; Lutz, B.; Poetz, O.; Pluschke, G.; Gertsch, J. Identification and Quantification of a New Family of Peptide Endocannabinoids (Pepcans) Showing Negative Allosteric Modulation at CB1 Receptors J. Biol. Chem. 2012, 287 (44) 36944-36967 10.1074/jbc.M112.382481
36. Khurana, L.; Ali, H. I.; Olszewska, T.; Ahn, K. H.; Damaraju, A.; Kendall, D. A.; Lu, D. Optimization of Chemical Functionalities of Indole-2-Carboxamides to Improve Allosteric Parameters for the Cannabinoid Receptor 1 (CB1) J. Med. Chem. 2014, 57 (7) 3040-3052 10.1021/jm5000112
37. Onaivi, E. S. Cannabinoid Receptors in Brain: Pharmacogenetics, Neuropharmacology, Neurotoxicology, and Potential Therapeutic Applications Int. Rev. Neurobiol. 2009, 88, 335-369 10.1016/S0074-7742(09)88012-4
38. Brown, S. M.; Wager-Miller, J.; Mackie, K. Cloning and Molecular Characterization of the Rat CB2 Cannabinoid Receptor Biochim. Biophys. Acta, Gene Struct. Expression 2002, 1576 (3) 255-264 10.1016/S0167-4781(02)00341-X
39. Ofek, O.; Karsak, M.; Leclerc, N.; Fogel, M.; Frenkel, B.; Wright, K.; Tam, J.; Attar-Namdar, M.; Kram, V.; Shohami, E. et al. Peripheral Cannabinoid Receptor, CB2 Proc. Natl. Acad. Sci. U. S. A. 2006, 103 (3) 696-701 10.1073/pnas.0504187103
40. Julien, B.; Grenard, P.; Teixeira-Clerc, F.; Van Nhieu, J. T.; Li, L.; Karsak, M.; Zimmer, A.; Mallat, A.; Lotersztajn, S. Antifibrogenic Role of the Cannabinoid Receptor CB2 in the Liver Gastroenterology 2005, 128 (3) 742-755 10.1053/j.gastro.2004.12.050
41. Duncan, M.; Mouihate, A.; Mackie, K.; Keenan, C. M.; Buckley, N. E.; Davison, J. S.; Patel, K. D.; Pittman, Q. J.; Sharkey, K. A. Cannabinoid CB2 Receptors in the Enteric Nervous System Modulate Gastrointestinal Contractility in Lipopolysaccharide-Treated Rats Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 295 (1) G78-G87 10.1152/ajpgi.90285.2008
42. Atwood, B. K.; Mackie, K. CB2: A Cannabinoid Receptor with an Identity Crisis Br. J. Pharmacol. 2010, 160 (3) 467-479 10.1111/j.1476-5381.2010.00729.x
43. Price, D. A.; Martinez, A. A.; Seillier, A.; Koek, W.; Acosta, Y.; Fernandez, E.; Strong, R.; Lutz, B.; Marsicano, G.; Roberts, J. L. et al. WIN55,212-2, a Cannabinoid Receptor Agonist, Protects against Nigrostriatal Cell Loss in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson's Disease Eur. J. Neurosci. 2009, 29 (11) 2177-2186 10.1111/j.1460-9568.2009.06764.x
44. Pietr, M.; Kozela, E.; Levy, R.; Rimmerman, N.; Lin, Y. H.; Stella, N.; Vogel, Z.; Juknat, A. Differential Changes in GPR55 during Microglial Cell Activation FEBS Lett. 2009, 583 (12) 2071-2076 10.1016/j.febslet.2009.05.028
45. Berdyshev, E. V. Cannabinoid Receptors and the Regulation of Immune Response Chem. Phys. Lipids 2000, 108 (1-2) 169-190 10.1016/S0009-3084(00)00195-X
46. Oz, M. Receptor-Independent Effects of Endocannabinoids on Ion Channels Curr. Pharm. Des. 2006, 12 (2) 227-239 10.2174/138161206775193073
47. Howlett, A. C. Cannabinoid Receptor Signaling Handb. Exp. Pharmacol. 2005, No. 168, 53-79 10.1007/3-540-26573-2
48. Galve-Roperh, I.; Chiurchiù, V.; Díaz-Alonso, J.; Bari, M.; Guzmán, M.; Maccarrone, M. Cannabinoid Receptor Signaling in Progenitor/stem Cell Proliferation and Differentiation Prog. Lipid Res. 2013, 52 (4) 633-650 10.1016/j.plipres.2013.05.004
49. Upham, B. L.; Rummel, A. M.; Carbone, J. M.; Trosko, J. E.; Ouyang, Y.; Crawford, R. B.; Kaminski, N. E. Cannabinoids Inhibit Gap Junctional Intercellular Communication and Activate ERK in a Rat Liver Epithelial Cell Line Int. J. Cancer 2003, 104 (1) 12-18 10.1002/ijc.10899
50. Merighi, S.; Gessi, S.; Varani, K.; Simioni, C.; Fazzi, D.; Mirandola, P.; Borea, P. A. Cannabinoid CB(2) Receptors Modulate ERK-1/2 Kinase Signalling and NO Release in Microglial Cells Stimulated with Bacterial Lipopolysaccharide Br. J. Pharmacol. 2012, 165 (6) 1773-1788 10.1111/j.1476-5381.2011.01673.x
51. Cunha, T. M.; Roman-Campos, D.; Lotufo, C. M.; Duarte, H. L.; Souza, G. R.; Verri, W. A.; Funez, M. I.; Dias, Q. M.; Schivo, I. R.; Domingues, A. C. et al. Morphine Peripheral Analgesia Depends on Activation of the PI3Kgamma/AKT/nNOS/NO/KATP Signaling Pathway Proc. Natl. Acad. Sci. U. S. A. 2010, 107 (9) 4442-4447 10.1073/pnas.0914733107
52. Murphy, S. Production of Nitric Oxide by Glial Cells: Regulation and Potential Roles in the CNS Glia 2000, 29 (1) 1-13 10.1002/(SICI)1098-1136(20000101)29:11::AID-GLIA13.0.CO;2-N
53. Merighi, S.; Gessi, S.; Varani, K.; Fazzi, D.; Mirandola, P.; Borea, P. A. Cannabinoid CB(2) Receptor Attenuates Morphine-Induced Inflammatory Responses in Activated Microglial Cells Br. J. Pharmacol. 2012, 166 (8) 2371-2385 10.1111/j.1476-5381.2012.01948.x
54. Guzmán, M.; Galve-Roperh, I.; Sánchez, C. Ceramide: A New Second Messenger of Cannabinoid Action Trends Pharmacol. Sci. 2001, 22 (1) 19-22 10.1016/S0165-6147(00)01586-8
55. Morel, L. J.; Giros, B.; Daugé, V. Adolescent Exposure to Chronic Delta-9-Tetrahydrocannabinol Blocks Opiate Dependence in Maternally Deprived Rats Neuropsychopharmacology 2009, 34 (11) 2469-2476 10.1038/npp.2009.70
56. Parolaro, D.; Rubino, T.; Viganò, D.; Massi, P.; Guidali, C.; Realini, N. Cellular Mechanisms Underlying the Interaction between Cannabinoid and Opioid System Curr. Drug Targets 2010, 11 (4) 393-405 10.2174/138945010790980367
57. Zoppi, S.; Madrigal, J. L.; Caso, J. R.; García-Gutiérrez, M. S.; Manzanares, J.; Leza, J. C.; García-Bueno, B. Regulatory Role of the Cannabinoid CB2 Receptor in Stress-Induced Neuroinflammation in Mice Br. J. Pharmacol. 2014, 171 (11) 2814-2826 10.1111/bph.12607
58. Gui, H.; Liu, X.; Wang, Z.-W.; He, D.-Y.; Su, D.-F.; Dai, S.-M. Expression of Cannabinoid Receptor 2 and Its Inhibitory Effects on Synovial Fibroblasts in Rheumatoid Arthritis Rheumatology (Oxford, U. K.) 2014, 53 (5) 802-809 10.1093/rheumatology/ket447
59. Guillot, A.; Hamdaoui, N.; Bizy, A.; Zoltani, K.; Souktani, R.; Zafrani, E.-S.; Mallat, A.; Lotersztajn, S.; Lafdil, F. Cannabinoid Receptor 2 Counteracts Interleukin-17-Induced Immune and Fibrogenic Responses in Mouse Liver Hepatology 2014, 59 (1) 296-306 10.1002/hep.26598
60. Wilkerson, J. L.; Gentry, K. R.; Dengler, E. C.; Wallace, J. A.; Kerwin, A. A.; Armijo, L. M.; Kuhn, M. N.; Thakur, G. A.; Makriyannis, A.; Milligan, E. D. Intrathecal Cannabilactone CB(2)R Agonist, AM1710, Controls Pathological Pain and Restores Basal Cytokine Levels Pain 2012, 153 (5) 1091-1106 10.1016/j.pain.2012.02.015
61. Gao, F.; Zhang, L.-H.; Su, T.-F.; Li, L.; Zhou, R.; Peng, M.; Wu, C.-H.; Yuan, X.-C.; Sun, N.; Meng, X.-F. et al. Signaling Mechanism of Cannabinoid Receptor-2 Activation-Induced B-Endorphin Release Mol. Neurobiol. 2015, 10.1007/s12035-015-9291-2
62. De Petrocellis, L.; Cascio, M. G.; Di Marzo, V. The Endocannabinoid System: A General View and Latest Additions Br. J. Pharmacol. 2004, 141 (5) 765-774 10.1038/sj.bjp.0705666
63. Maccarrone, M.; Bab, I.; Bíró, T.; Cabral, G. A.; Dey, S. K.; Di Marzo, V.; Konje, J. C.; Kunos, G.; Mechoulam, R.; Pacher, P. et al. Endocannabinoid Signaling at the Periphery: 50 Years after THC Trends Pharmacol. Sci. 2015, 36 (5) 277-296 10.1016/j.tips.2015.02.008
64. Pagotto, U.; Marsicano, G.; Cota, D.; Lutz, B.; Pasquali, R. The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance Endocr. Rev. 2006, 27 (1) 73-100 10.1210/er.2005-0009
65. Wang, J.; Ueda, N. Biology of Endocannabinoid Synthesis System Prostaglandins Other Lipid Mediators 2009, 89 (3-4) 112-119 10.1016/j.prostaglandins.2008.12.002
66. Bisogno, T.; Ligresti, A.; Di Marzo, V. The Endocannabinoid Signalling System: Biochemical Aspects Pharmacol., Biochem. Behav. 2005, 81 (2) 224-238 10.1016/j.pbb.2005.01.027
67. Schmid, H. H. O.; Berdyshev, E. V. Cannabinoid Receptor-Inactive N-Acylethanolamines and Other Fatty Acid Amides: Metabolism and Function Prostaglandins, Leukotrienes Essent. Fatty Acids 2002, 66 (2-3) 363-376 10.1054/plef.2001.0348
68. Bisogno, T.; De Petrocellis, L.; Di Marzo, V. Fatty Acid Amide Hydrolase, an Enzyme with Many Bioactive Substrates. Possible Therapeutic Implications Curr. Pharm. Des. 2002, 8 (7) 533-547 10.2174/1381612023395655
69. Serra, G.; Bogliolo, V.; Garzia, A.; Zazzara, F.; Koukopoulos, A.; Demontis, F. The Role of the Endocannabinoid System in the Pathophysiology of Mood Disorders J. Psychopathol. 2011, 17, 78-91
70. Fowler, C. J. The Cannabinoid System and Its Pharmacological Manipulation - a Review, with Emphasis upon the Uptake and Hydrolysis of Anandamide Fundam. Clin. Pharmacol. 2006, 20 (6) 549-562 10.1111/j.1472-8206.2006.00442.x
71. Naidoo, V.; Karanian, D. A.; Vadivel, S. K.; Locklear, J. R.; Wood, J. T.; Nasr, M.; Quizon, P. M. P.; Graves, E. E.; Shukla, V.; Makriyannis, A. et al. Equipotent Inhibition of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase-Dual Targets of the Endocannabinoid System to Protect against Seizure Pathology Neurotherapeutics 2012, 9 (4) 801-813 10.1007/s13311-011-0100-y
72. Hwang, J.; Adamson, C.; Butler, D.; Janero, D. R.; Makriyannis, A.; Bahr, B. A. Enhancement of Endocannabinoid Signaling by Fatty Acid Amide Hydrolase Inhibition: A Neuroprotective Therapeutic Modality Life Sci. 2010, 86 (15-16) 615-623 10.1016/j.lfs.2009.06.003
73. Lichtman, A. H.; Leung, D.; Shelton, C. C.; Saghatelian, A.; Hardouin, C.; Boger, D. L.; Cravatt, B. F. Reversible Inhibitors of Fatty Acid Amide Hydrolase That Promote Analgesia: Evidence for an Unprecedented Combination of Potency and Selectivity J. Pharmacol. Exp. Ther. 2004, 311 (2) 441-448 10.1124/jpet.104.069401
74. Ross, R. A. Anandamide and Vanilloid TRPV1 Receptors Br. J. Pharmacol. 2003, 140 (5) 790-801 10.1038/sj.bjp.0705467
75. Di Marzo, V.; De Petrocellis, L. Why Do Cannabinoid Receptors Have More than One Endogenous Ligand? Philos. Trans. R. Soc., B 2012, 367 (1607) 3216-3228 10.1098/rstb.2011.0382
76. Malek, N.; Popiolek-Barczyk, K.; Mika, J.; Przewlocka, B.; Starowicz, K. Anandamide, Acting via CB2 Receptors, Alleviates LPS-Induced Neuroinflammation in Rat Primary Microglial Cultures Neural Plast. 2015, 2015, 130639 10.1155/2015/130639
77. Karaliota, S.; Siafaka-Kapadai, A.; Gontinou, C.; Psarra, K.; Mavri-Vavayanni, M. Anandamide Increases the Differentiation of Rat Adipocytes and Causes PPARgamma and CB1 Receptor Upregulation Obesity 2009, 17 (10) 1830-1838 10.1038/oby.2009.177
78. Miller, A. M.; Stella, N. CB2 Receptor-Mediated Migration of Immune Cells: It Can Go Either Way Br. J. Pharmacol. 2008, 153 (2) 299-308 10.1038/sj.bjp.0707523
79. Ronco, A. M.; Llanos, M.; Tamayo, D.; Hirsch, S. Anandamide Inhibits Endothelin-1 Production by Human Cultured Endothelial Cells: A New Vascular Action of This Endocannabinoid Pharmacology 2007, 79 (1) 12-16 10.1159/000097072
80. Maldonado, R.; Berrendero, F.; Ozaita, A.; Robledo, P. Neurochemical Basis of Cannabis Addiction Neuroscience 2011, 181, 1-17 10.1016/j.neuroscience.2011.02.035
81. Aso, E.; Ferrer, I. Cannabinoids for Treatment of Alzheimer's Disease: Moving toward the Clinic Front. Pharmacol. 2014, 5, 37 10.3389/fphar.2014.00037
82. Savonenko, A. V.; Melnikova, T.; Wang, Y.; Ravert, H.; Gao, Y.; Koppel, J.; Lee, D.; Pletnikova, O.; Cho, E.; Sayyida, N. et al. Cannabinoid CB2 Receptors in a Mouse Model of Aβ Amyloidosis: Immunohistochemical Analysis and Suitability as a PET Biomarker of Neuroinflammation PLoS One 2015, 10 (6) e0129618 10.1371/journal.pone.0129618
83. Rogers, N. Cannabinoid Receptor with an Identity Crisis Gets a Second Look Nat. Med. 2015, 21 (9) 966-967 10.1038/nm0915-966
84. Sipe, J. C.; Arbour, N.; Gerber, A.; Beutler, E. Reduced Endocannabinoid Immune Modulation by a Common Cannabinoid 2 (CB2) Receptor Gene Polymorphism: Possible Risk for Autoimmune Disorders J. Leukocyte Biol. 2005, 78 (1) 231-238 10.1189/jlb.0205111
85. Karsak, M.; Cohen-Solal, M.; Freudenberg, J.; Ostertag, A.; Morieux, C.; Kornak, U.; Essig, J.; Erxlebe, E.; Bab, I.; Kubisch, C. et al. Cannabinoid Receptor Type 2 Gene Is Associated with Human Osteoporosis Hum. Mol. Genet. 2005, 14 (22) 3389-3396 10.1093/hmg/ddi370
86. Borea, P. A.; Dalpiaz, A.; Varani, K.; Gilli, P.; Gilli, G. Can Thermodynamic Measurements of Receptor Binding Yield Information on Drug Affinity and Efficacy? Biochem. Pharmacol. 2000, 60 (11) 1549-1556 10.1016/S0006-2952(00)00368-3
87. Merighi, S.; Simioni, C.; Gessi, S.; Varani, K.; Borea, P. A. Binding Thermodynamics at the Human Cannabinoid CB1 and CB2 Receptors Biochem. Pharmacol. 2010, 79 (3) 471-477 10.1016/j.bcp.2009.09.009
88. Varani, K.; Merighi, S.; Gessi, S.; Klotz, K. N.; Leung, E.; Baraldi, P. G.; Cacciari, B.; Romagnoli, R.; Spalluto, G.; Borea, P. A. [(3)H]MRE 3008F20: A Novel Antagonist Radioligand for the Pharmacological and Biochemical Characterization of Human A(3) Adenosine Receptors Mol. Pharmacol. 2000, 57 (5) 968-975
89. Merighi, S.; Varani, K.; Gessi, S.; Klotz, K. N.; Leung, E.; Baraldi, P. G.; Borea, P. A. Binding Thermodynamics at the Human A(3) Adenosine Receptor Biochem. Pharmacol. 2002, 63 (2) 157-161 10.1016/S0006-2952(01)00825-5
90. Gessi, S.; Fogli, E.; Sacchetto, V.; Varani, K.; Merighi, S.; Leung, E.; Lennan, S.; Mac Borea, P. A. Thermodynamics of A2B Adenosine Receptor Binding Discriminates Agonistic from Antagonistic Behaviour Biochem. Pharmacol. 2008, 75 (2) 562-569 10.1016/j.bcp.2007.09.003
91. McKallip, R. J.; Lombard, C.; Fisher, M.; Martin, B. R.; Ryu, S.; Grant, S.; Nagarkatti, P. S.; Nagarkatti, M. Targeting CB2 Cannabinoid Receptors as a Novel Therapy to Treat Malignant Lymphoblastic Disease Blood 2002, 100 (2) 627-634 10.1182/blood-2002-01-0098
92. Robinson, R. H.; Meissler, J. J.; Breslow-Deckman, J. M.; Gaughan, J.; Adler, M. W.; Eisenstein, T. K. Cannabinoids Inhibit T-Cells via Cannabinoid Receptor 2 in an in Vitro Assay for Graft Rejection, the Mixed Lymphocyte Reaction J. Neuroimmune Pharmacol. 2013, 8 (5) 1239-1250 10.1007/s11481-013-9485-1
93. Rieder, S. A.; Chauhan, A.; Singh, U.; Nagarkatti, M.; Nagarkatti, P. Cannabinoid-Induced Apoptosis in Immune Cells as a Pathway to Immunosuppression Immunobiology 2010, 215 (8) 598-605 10.1016/j.imbio.2009.04.001
94. Jean-Gilles, L.; Braitch, M.; Latif, M. L.; Aram, J.; Fahey, A. J.; Edwards, L. J.; Robins, R. A.; Tanasescu, R.; Tighe, P. J.; Gran, B. et al. Effects of pro-Inflammatory Cytokines on Cannabinoid CB1 and CB2 Receptors in Immune Cells Acta Physiol. 2015, 214 (1) 63-74 10.1111/apha.12474
95. Chen, Y.; Buck, J. Cannabinoids Protect Cells from Oxidative Cell Death: A Receptor-Independent Mechanism J. Pharmacol. Exp. Ther. 2000, 293 (3) 807-812
96. Martínez-Orgado, J.; Fernández-López, D.; Lizasoain, I.; Romero, J. The Seek of Neuroprotection: Introducing Cannabinoids Recent Pat. CNS Drug Discovery 2007, 2 (2) 131-139 10.2174/157488907780832724
97. Mecha, M.; Torrao, A. S.; Mestre, L.; Carrillo-Salinas, F. J.; Mechoulam, R.; Guaza, C. Cannabidiol Protects Oligodendrocyte Progenitor Cells from Inflammation-Induced Apoptosis by Attenuating Endoplasmic Reticulum Stress Cell Death Dis. 2012, 3, e331 10.1038/cddis.2012.71
98. Patel, K. D.; Davison, J. S.; Pittman, Q. J.; Sharkey, K. A. Cannabinoid CB(2) Receptors in Health and Disease Curr. Med. Chem. 2010, 17 (14) 1394-1410 10.2174/092986710790980041
99. Pereira, J. P.; An, J.; Xu, Y.; Huang, Y.; Cyster, J. G. Cannabinoid Receptor 2 Mediates the Retention of Immature B Cells in Bone Marrow Sinusoids Nat. Immunol. 2009, 10 (4) 403-411 10.1038/ni.1710
100. Sophocleous, A.; Börjesson, A. E.; Salter, D. M.; Ralston, S. H. The Type 2 Cannabinoid Receptor Regulates Susceptibility to Osteoarthritis in Mice Osteoarthritis Cartilage 2015, 23 (9) 1586-1594 10.1016/j.joca.2015.04.020
101. Gui, H.; Tong, Q.; Qu, W.; Mao, C.-M.; Dai, S.-M. The Endocannabinoid System and Its Therapeutic Implications in Rheumatoid Arthritis Int. Immunopharmacol. 2015, 26 (1) 86-91 10.1016/j.intimp.2015.03.006
102. Richardson, D.; Pearson, R. G.; Kurian, N.; Latif, M. L.; Garle, M. J.; Barrett, D. A.; Kendall, D. A.; Scammell, B. E.; Reeve, A. J.; Chapman, V. Characterisation of the Cannabinoid Receptor System in Synovial Tissue and Fluid in Patients with Osteoarthritis and Rheumatoid Arthritis Arthritis Res. Ther. 2008, 10 (2) R43 10.1186/ar2401
103. Montecucco, F.; Burger, F.; Mach, F.; Steffens, S. CB2 Cannabinoid Receptor Agonist JWH-015 Modulates Human Monocyte Migration through Defined Intracellular Signaling Pathways Am. J. Physiol. Heart Circ. Physiol. 2008, 294 (3) H1145-H1155 10.1152/ajpheart.01328.2007
104. Gaffal, E.; Cron, M.; Glodde, N.; Tüting, T. Anti-Inflammatory Activity of Topical THC in DNFB-Mediated Mouse Allergic Contact Dermatitis Independent of CB1 and CB2 Receptors Allergy 2013, 68 (8) 994-1000 10.1111/all.12183
105. Han, S.; Thatte, J.; Buzard, D. J.; Jones, R. M. Therapeutic Utility of Cannabinoid Receptor Type 2 (CB(2)) Selective Agonists J. Med. Chem. 2013, 56 (21) 8224-8256 10.1021/jm4005626
106. Xu, H.; Cheng, C. L.; Chen, M.; Manivannan, A.; Cabay, L.; Pertwee, R. G.; Coutts, A.; Forrester, J. V. Anti-Inflammatory Property of the Cannabinoid Receptor-2-Selective Agonist JWH-133 in a Rodent Model of Autoimmune Uveoretinitis J. Leukocyte Biol. 2007, 82 (3) 532-541 10.1189/jlb.0307159
107. Carlisle, S. J.; Marciano-Cabral, F.; Staab, A.; Ludwick, C.; Cabral, G. A. Differential Expression of the CB2 Cannabinoid Receptor by Rodent Macrophages and Macrophage-like Cells in Relation to Cell Activation Int. Immunopharmacol. 2002, 2 (1) 69-82 10.1016/S1567-5769(01)00147-3
108. Eljaschewitsch, E.; Witting, A.; Mawrin, C.; Lee, T.; Schmidt, P. M.; Wolf, S.; Hoertnagl, H.; Raine, C. S.; Schneider-Stock, R.; Nitsch, R. et al. The Endocannabinoid Anandamide Protects Neurons during CNS Inflammation by Induction of MKP-1 in Microglial Cells Neuron 2006, 49 (1) 67-79 10.1016/j.neuron.2005.11.027
109. Benito, C.; Tolón, R. M.; Pazos, M. R.; Núnfnof;ez, E.; Castillo, A. I.; Romero, J. Cannabinoid CB2 Receptors in Human Brain Inflammation Br. J. Pharmacol. 2008, 153 (2) 277-285 10.1038/sj.bjp.0707505
110. Benito, C.; Kim, W.-K.; Chavarría, I.; Hillard, C. J.; Mackie, K.; Tolón, R. M.; Williams, K.; Williams, K.; Romero, J. A Glial Endogenous Cannabinoid System Is Upregulated in the Brains of Macaques with Simian Immunodeficiency Virus-Induced Encephalitis J. Neurosci. 2005, 25 (10) 2530-2536 10.1523/JNEUROSCI.3923-04.2005
111. Concannon, R. M.; Okine, B. N.; Finn, D. P.; Dowd, E. Differential Upregulation of the Cannabinoid CB2 Receptor in Neurotoxic and Inflammation-Driven Rat Models of Parkinson's Disease Exp. Neurol. 2015, 269, 133-141 10.1016/j.expneurol.2015.04.007
112. Gómez-Gálvez, Y.; Palomo-Garo, C.; Fernández-Ruiz, J.; García, C. Potential of the Cannabinoid CB2 Receptor as a Pharmacological Target against Inflammation in Parkinson's Disease Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2015, 64, 200-208 10.1016/j.pnpbp.2015.03.017
113. Rajesh, M.; Mukhopadhyay, P.; Haskó, G.; Huffman, J. W.; Mackie, K.; Pacher, P. CB2 Cannabinoid Receptor Agonists Attenuate TNF-Alpha-Induced Human Vascular Smooth Muscle Cell Proliferation and Migration Br. J. Pharmacol. 2008, 153 (2) 347-357 10.1038/sj.bjp.0707569
114. Kurihara, R.; Tohyama, Y.; Matsusaka, S.; Naruse, H.; Kinoshita, E.; Tsujioka, T.; Katsumata, Y.; Yamamura, H. Effects of Peripheral Cannabinoid Receptor Ligands on Motility and Polarization in Neutrophil-like HL60 Cells and Human Neutrophils J. Biol. Chem. 2006, 281 (18) 12908-12918 10.1074/jbc.M510871200
115. Mecha, M.; Feliú, A.; Carrillo-Salinas, F. J.; Rueda-Zubiaurre, A.; Ortega-Gutiérrez, S.; de Sola, R. G.; Guaza, C. Endocannabinoids Drive the Acquisition of an Alternative Phenotype in Microglia Brain, Behav., Immun. 2015, 49, 233-245 10.1016/j.bbi.2015.06.002
116. Adhikary, S.; Kocieda, V. P.; Yen, J.-H.; Tuma, R. F.; Ganea, D. Signaling through Cannabinoid Receptor 2 Suppresses Murine Dendritic Cell Migration by Inhibiting Matrix Metalloproteinase 9 Expression Blood 2012, 120 (18) 3741-3749 10.1182/blood-2012-06-435362
117. Golech, S. A.; McCarron, R. M.; Chen, Y.; Bembry, J.; Lenz, F.; Mechoulam, R.; Shohami, E.; Spatz, M. Human Brain Endothelium: Coexpression and Function of Vanilloid and Endocannabinoid Receptors Mol. Brain Res. 2004, 132 (1) 87-92 10.1016/j.molbrainres.2004.08.025
118. Sospedra, M.; Martin, R. Immunology of Multiple Sclerosis Annu. Rev. Immunol. 2005, 23, 683-747 10.1146/annurev.immunol.23.021704.115707
119. Maresz, K.; Carrier, E. J.; Ponomarev, E. D.; Hillard, C. J.; Dittel, B. N. Modulation of the Cannabinoid CB2 Receptor in Microglial Cells in Response to Inflammatory Stimuli J. Neurochem. 2005, 95 (2) 437-445 10.1111/j.1471-4159.2005.03380.x
120. Ehrhart, J.; Obregon, D.; Mori, T.; Hou, H.; Sun, N.; Bai, Y.; Klein, T.; Fernandez, F.; Tan, J.; Shytle, R. D. Stimulation of Cannabinoid Receptor 2 (CB2) Suppresses Microglial Activation J. Neuroinflammation 2005, 2, 29 10.1186/1742-2094-2-29
121. Maresz, K.; Pryce, G.; Ponomarev, E. D.; Marsicano, G.; Croxford, J. L.; Shriver, L. P.; Ledent, C.; Cheng, X.; Carrier, E. J.; Mann, M. K. et al. Direct Suppression of CNS Autoimmune Inflammation via the Cannabinoid Receptor CB1 on Neurons and CB2 on Autoreactive T Cells Nat. Med. 2007, 13 (4) 492-497 10.1038/nm1561
122. Palazuelos, J.; Davoust, N.; Julien, B.; Hatterer, E.; Aguado, T.; Mechoulam, R.; Benito, C.; Romero, J.; Silva, A.; Guzmán, M. et al. The CB(2) Cannabinoid Receptor Controls Myeloid Progenitor Trafficking: Involvement in the Pathogenesis of an Animal Model of Multiple Sclerosis J. Biol. Chem. 2008, 283 (19) 13320-13329 10.1074/jbc.M707960200
123. Zhang, M.; Martin, B. R.; Adler, M. W.; Razdan, R. J.; Kong, W.; Ganea, D.; Tuma, R. F. Modulation of Cannabinoid Receptor Activation as a Neuroprotective Strategy for EAE and Stroke J. Neuroimmune Pharmacol. 2009, 4 (2) 249-259 10.1007/s11481-009-9148-4
124. Pava, M. J.; Woodward, J. J. A Review of the Interactions between Alcohol and the Endocannabinoid System: Implications for Alcohol Dependence and Future Directions for Research Alcohol 2012, 46 (3) 185-204 10.1016/j.alcohol.2012.01.002
125. Pradier, B.; Erxlebe, E.; Markert, A.; Rácz, I. Interaction of Cannabinoid Receptor 2 and Social Environment Modulates Chronic Alcohol Consumption Behav. Brain Res. 2015, 287, 163-171 10.1016/j.bbr.2015.03.051
126. Onaivi, E. S.; Ishiguro, H.; Gong, J.-P.; Patel, S.; Meozzi, P. A.; Myers, L.; Perchuk, A.; Mora, Z.; Tagliaferro, P. A.; Gardner, E. et al. Functional Expression of Brain Neuronal CB2 Cannabinoid Receptors Are Involved in the Effects of Drugs of Abuse and in Depression Ann. N. Y. Acad. Sci. 2008, 1139, 434-449 10.1196/annals.1432.036
127. Onaivi, E. S.; Carpio, O.; Ishiguro, H.; Schanz, N.; Uhl, G. R.; Benno, R. Behavioral Effects of CB2 Cannabinoid Receptor Activation and Its Influence on Food and Alcohol Consumption Ann. N. Y. Acad. Sci. 2008, 1139, 426-433 10.1196/annals.1432.035
128. Ishiguro, H.; Iwasaki, S.; Teasenfitz, L.; Higuchi, S.; Horiuchi, Y.; Saito, T.; Arinami, T.; Onaivi, E. S. Involvement of Cannabinoid CB2 Receptor in Alcohol Preference in Mice and Alcoholism in Humans Pharmacogenomics J. 2007, 7 (6) 380-385 10.1038/sj.tpj.6500431
129. Gong, J.-P.; Onaivi, E. S.; Ishiguro, H.; Liu, Q.-R.; Tagliaferro, P. A.; Brusco, A.; Uhl, G. R. Cannabinoid CB2 Receptors: Immunohistochemical Localization in Rat Brain Brain Res. 2006, 1071 (1) 10-23 10.1016/j.brainres.2005.11.035
130. Brusco, A.; Tagliaferro, P.; Saez, T.; Onaivi, E. S. Postsynaptic Localization of CB2 Cannabinoid Receptors in the Rat Hippocampus Synapse 2008, 62 (12) 944-949 10.1002/syn.20569
131. Ishiguro, H.; Carpio, O.; Horiuchi, Y.; Shu, A.; Higuchi, S.; Schanz, N.; Benno, R.; Arinami, T.; Onaivi, E. S. A Nonsynonymous Polymorphism in Cannabinoid CB2 Receptor Gene Is Associated with Eating Disorders in Humans and Food Intake Is Modified in Mice by Its Ligands Synapse 2010, 64 (1) 92-96 10.1002/syn.20714
132. Pacher, P.; Mukhopadhyay, P.; Mohanraj, R.; Godlewski, G.; Bátkai, S.; Kunos, G. Modulation of the Endocannabinoid System in Cardiovascular Disease: Therapeutic Potential and Limitations Hypertension 2008, 52 (4) 601-607 10.1161/HYPERTENSIONAHA.105.063651
133. Pacher, P.; Haskó, G. Endocannabinoids and Cannabinoid Receptors in Ischaemia-Reperfusion Injury and Preconditioning Br. J. Pharmacol. 2008, 153 (2) 252-262 10.1038/sj.bjp.0707582
134. Moris, D.; Georgopoulos, S.; Felekouras, E.; Patsouris, E.; Theocharis, S. The Effect of Endocannabinoid System in Ischemia-Reperfusion Injury: A Friend or a Foe? Expert Opin. Ther. Targets 2015, 1-15 10.1517/14728222.2015.1043268
135. Hillard, C. J. Role of Cannabinoids and Endocannabinoids in Cerebral Ischemia Curr. Pharm. Des. 2008, 14 (23) 2347-2361 10.2174/138161208785740054
136. Rajesh, M.; Pan, H.; Mukhopadhyay, P.; Bátkai, S.; Osei-Hyiaman, D.; Haskó, G.; Liaudet, L.; Gao, B.; Pacher, P. Cannabinoid-2 Receptor Agonist HU-308 Protects against Hepatic Ischemia/reperfusion Injury by Attenuating Oxidative Stress, Inflammatory Response, and Apoptosis J. Leukocyte Biol. 2007, 82 (6) 1382-1389 10.1189/jlb.0307180
137. Montecucco, F.; Lenglet, S.; Braunersreuther, V.; Burger, F.; Pelli, G.; Bertolotto, M.; Mach, F.; Steffens, S. CB(2) Cannabinoid Receptor Activation Is Cardioprotective in a Mouse Model of Ischemia/reperfusion J. Mol. Cell. Cardiol. 2009, 46 (5) 612-620 10.1016/j.yjmcc.2008.12.014
138. Duerr, G.; Heinemann, J.; Kley, J.; Roell, W.; Ottersbach, A.; Zimmer, A.; Lutz, B.; Welz, A.; Dewald, O. P80 ∗ Cannabinoid Receptor CB2 Prevents Development of Heart Failure in a Murine Model of Pressure Overload Cardiovasc. Res. 2014, 103 (Suppl 1) S13-S13 10.1093/cvr/cvu082.23
139. Duerr, G. D.; Heinemann, J. C.; Suchan, G.; Kolobara, E.; Wenzel, D.; Geisen, C.; Matthey, M.; Passe-Tietjen, K.; Mahmud, W.; Ghanem, A. et al. The Endocannabinoid-CB2 Receptor Axis Protects the Ischemic Heart at the Early Stage of Cardiomyopathy Basic Res. Cardiol. 2014, 109 (4) 425 10.1007/s00395-014-0425-x
140. Di Filippo, C.; Rossi, F.; Rossi, S.; D'Amico, M. Cannabinoid CB2 Receptor Activation Reduces Mouse Myocardial Ischemia-Reperfusion Injury: Involvement of Cytokine/chemokines and PMN J. Leukocyte Biol. 2004, 75 (3) 453-459 10.1189/jlb.0703303
141. Hansson, G. K. Inflammation, Atherosclerosis, and Coronary Artery Disease N. Engl. J. Med. 2005, 352 (16) 1685-1695 10.1056/NEJMra043430
142. Steffens, S.; Veillard, N. R.; Arnaud, C.; Pelli, G.; Burger, F.; Staub, C.; Karsak, M.; Zimmer, A.; Frossard, J.-L.; Mach, F. Low Dose Oral Cannabinoid Therapy Reduces Progression of Atherosclerosis in Mice Nature 2005, 434 (7034) 782-786 10.1038/nature03389
143. Arai, S.; Shelton, J. M.; Chen, M.; Bradley, M. N.; Castrillo, A.; Bookout, A. L.; Mak, P. A.; Edwards, P. A.; Mangelsdorf, D. J.; Tontonoz, P. et al. A Role for the Apoptosis Inhibitory Factor AIM/Spalpha/Api6 in Atherosclerosis Development Cell Metab. 2005, 1 (3) 201-213 10.1016/j.cmet.2005.02.002
144. Chiurchiù, V.; Lanuti, M.; Catanzaro, G.; Fezza, F.; Rapino, C.; Maccarrone, M. Detailed Characterization of the Endocannabinoid System in Human Macrophages and Foam Cells, and Anti-Inflammatory Role of Type-2 Cannabinoid Receptor Atherosclerosis 2014, 233 (1) 55-63 10.1016/j.atherosclerosis.2013.12.042
145. Liu, J.; Thewke, D. P.; Su, Y. R.; Linton, M. F.; Fazio, S.; Sinensky, M. S. Reduced Macrophage Apoptosis Is Associated with Accelerated Atherosclerosis in Low-Density Lipoprotein Receptor-Null Mice Arterioscler., Thromb., Vasc. Biol. 2005, 25 (1) 174-179 10.1161/01.ATV.0000148548.47755.22
146. Carbone, F.; Mach, F.; Vuilleumier, N.; Montecucco, F. Cannabinoid Receptor Type 2 Activation in Atherosclerosis and Acute Cardiovascular Diseases Curr. Med. Chem. 2014, 21 (35) 4046-4058 10.2174/0929867321666140915141332
147. Malik, Z.; Baik, D.; Schey, R. The Role of Cannabinoids in Regulation of Nausea and Vomiting, and Visceral Pain Curr. Gastroenterol. Rep. 2015, 17 (2) 429 10.1007/s11894-015-0429-1
148. Storr, M.; Gaffal, E.; Saur, D.; Schusdziarra, V.; Allescher, H. D. Effect of Cannabinoids on Neural Transmission in Rat Gastric Fundus Can. J. Physiol. Pharmacol. 2002, 80 (1) 67-76 10.1139/y02-005
149. Siegmund, S. V.; Schwabe, R. F. Endocannabinoids and Liver Disease. II. Endocannabinoids in the Pathogenesis and Treatment of Liver Fibrosis Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 294 (2) G357-G362 10.1152/ajpgi.00456.2007
150. Xu, X.; Liu, Y.; Huang, S.; Liu, G.; Xie, C.; Zhou, J.; Fan, W.; Li, Q.; Wang, Q.; Zhong, D. et al. Overexpression of Cannabinoid Receptors CB1 and CB2 Correlates with Improved Prognosis of Patients with Hepatocellular Carcinoma Cancer Genet. Cytogenet. 2006, 171 (1) 31-38 10.1016/j.cancergencyto.2006.06.014
151. Baldassarre, M.; Giannone, F. A.; Napoli, L.; Tovoli, A.; Ricci, C. S.; Tufoni, M.; Caraceni, P. The Endocannabinoid System in Advanced Liver Cirrhosis: Pathophysiological Implication and Future Perspectives Liver Int. 2013, 33 (9) 1298-1308 10.1111/liv.12263
152. Mulè, F.; Amato, A.; Baldassano, S.; Serio, R. Involvement of CB1 and CB2 Receptors in the Modulation of Cholinergic Neurotransmission in Mouse Gastric Preparations Pharmacol. Res. 2007, 56 (3) 185-192 10.1016/j.phrs.2007.06.002
153. Kurjak, M.; Hamel, A. M.; Allescher, H. D.; Schusdziarra, V.; Storr, M. Differential Stimulatory Effects of Cannabinoids on VIP Release and NO Synthase Activity in Synaptosomal Fractions from Rat Ileum Neuropeptides 2008, 42 (5-6) 623-632 10.1016/j.npep.2008.08.003
154. Rhee, S. H.; Pothoulakis, C.; Mayer, E. A. Principles and Clinical Implications of the Brain-Gut-Enteric Microbiota Axis Nat. Rev. Gastroenterol. Hepatol. 2009, 6 (5) 306-314 10.1038/nrgastro.2009.35
155. Ihenetu, K.; Molleman, A.; Parsons, M. E.; Whelan, C. J. Inhibition of Interleukin-8 Release in the Human Colonic Epithelial Cell Line HT-29 by Cannabinoids Eur. J. Pharmacol. 2003, 458 (1-2) 207-215 10.1016/S0014-2999(02)02698-5
156. Mayer, E. A.; Collins, S. M. Evolving Pathophysiologic Models of Functional Gastrointestinal Disorders Gastroenterology 2002, 122 (7) 2032-2048 10.1053/gast.2002.33584
157. Fichna, J.; Bawa, M.; Thakur, G. A.; Tichkule, R.; Makriyannis, A.; McCafferty, D.-M.; Sharkey, K. A.; Storr, M. Cannabinoids Alleviate Experimentally Induced Intestinal Inflammation by Acting at Central and Peripheral Receptors PLoS One 2014, 9 (10) e109115 10.1371/journal.pone.0109115
158. Kimball, E. S.; Schneider, C. R.; Wallace, N. H.; Hornby, P. J. Agonists of Cannabinoid Receptor 1 and 2 Inhibit Experimental Colitis Induced by Oil of Mustard and by Dextran Sulfate Sodium Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 291 (2) G364-G371 10.1152/ajpgi.00407.2005
159. Borrelli, F.; Romano, B.; Petrosino, S.; Pagano, E.; Capasso, R.; Coppola, D.; Battista, G.; Orlando, P.; Di Marzo, V.; Izzo, A. A. Palmitoylethanolamide, a Naturally Occurring Lipid, Is an Orally Effective Intestinal Anti-Inflammatory Agent Br. J. Pharmacol. 2015, 172 (1) 142-158 10.1111/bph.12907
160. Cui, Y.-Y.; D'Agostino, B.; Risse, P.-A.; Marrocco, G.; Naline, E.; Zhang, Y.; Chen, H.-Z.; Finance, O.; Rinaldi-Carmona, M.; Rossi, F. et al. Cannabinoid CB(2) Receptor Activation Prevents Bronchoconstriction and Airway Oedema in a Model of Gastro-Oesophageal Reflux Eur. J. Pharmacol. 2007, 573 (1-3) 206-213 10.1016/j.ejphar.2007.06.040
161. Belvisi, M. G.; Patel, H. J.; Freund-Michel, V.; Hele, D. J.; Crispino, N.; Birrell, M. A. Inhibitory Activity of the Novel CB2 Receptor Agonist, GW833972A, on Guinea-Pig and Human Sensory Nerve Function in the Airways Br. J. Pharmacol. 2008, 155 (4) 547-557 10.1038/bjp.2008.298
162. Gkoumassi, E.; Dekkers, B. G. J.; Dröge, M. J.; Elzinga, C. R. S.; Schmidt, M.; Meurs, H.; Zaagsma, J.; Nelemans, S. A. Virodhamine and CP55,940 Modulate cAMP Production and IL-8 Release in Human Bronchial Epithelial Cells Br. J. Pharmacol. 2007, 151 (7) 1041-1048 10.1038/sj.bjp.0707320
163. Maher, S. A.; Dubuis, E. D.; Belvisi, M. G. G-Protein Coupled Receptors Regulating Cough Curr. Opin. Pharmacol. 2011, 11 (3) 248-253 10.1016/j.coph.2011.06.005
164. Barnes, P. J. The Problem of Cough and Development of Novel Antitussives Pulm. Pharmacol. Ther. 2007, 20 (4) 416-422 10.1016/j.pupt.2006.11.001
165. Liu, M.; Su, M.; Wang, Y.; Wei, W.; Qin, L.; Liu, X.; Tian, M.; Qian, C. Effect of Melilotus Extract on Lung Injury by Upregulating the Expression of Cannabinoid CB2 Receptors in Septic Rats BMC Complementary Altern. Med. 2014, 14, 94 10.1186/1472-6882-14-94
166. Pacher, P.; Mechoulam, R. Is Lipid Signaling through Cannabinoid 2 Receptors Part of a Protective System? Prog. Lipid Res. 2011, 50 (2) 193-211 10.1016/j.plipres.2011.01.001
167. Sun, Y.-X.; Xu, A.-H.; Yang, Y.; Zhang, J.-X.; Yu, A.-W. Activation of Cannabinoid Receptor 2 Enhances Osteogenic Differentiation of Bone Marrow Derived Mesenchymal Stem Cells BioMed Res. Int. 2015, 2015, 874982 10.1155/2015/874982
168. Rossi, F.; Bellini, G.; Tortora, C.; Bernardo, M. E.; Luongo, L.; Conforti, A.; Starc, N.; Manzo, I.; Nobili, B.; Locatelli, F. et al. CB2 and TRPV1 Receptors Oppositely Modulate in Vitro Human Osteoblast Activity Pharmacol. Res. 2015, 99, 194 10.1016/j.phrs.2015.06.010
169. Idris, A. I.; van't Hof, R. J.; Greig, I. R.; Ridge, S. A.; Baker, D.; Ross, R. A.; Ralston, S. H. Regulation of Bone Mass, Bone Loss and Osteoclast Activity by Cannabinoid Receptors Nat. Med. 2005, 11 (7) 774-779 10.1038/nm1255
170. Zofková, I.; Matucha, P. New Insights into the Physiology of Bone Regulation: The Role of Neurohormones Physiol. Res. 2014, 63 (4) 421-427
171. Smoum, R.; Baraghithy, S.; Chourasia, M.; Breuer, A.; Mussai, N.; Attar-Namdar, M.; Kogan, N. M.; Raphael, B.; Bolognini, D.; Cascio, M. G. CB2 Cannabinoid Receptor Agonist Enantiomers HU-433 and HU-308: An Inverse Relationship between Binding Affinity and Biological Potency Proc. Natl. Acad. Sci. U. S. A. 2015, 112, 8774-8779 10.1073/pnas.1503395112
172. Lunn, C. A.; Fine, J.; Rojas-Triana, A.; Jackson, J. V.; Lavey, B.; Kozlowski, J. A.; Hipkin, R. W.; Lundell, D. J.; Bober, L. Cannabinoid CB(2)-Selective Inverse Agonist Protects against Antigen-Induced Bone Loss Immunopharmacol. Immunotoxicol. 2007, 29 (3-4) 387-401 10.1080/08923970701674997
173. Cridge, B. J.; Rosengren, R. J. Critical Appraisal of the Potential Use of Cannabinoids in Cancer Management Cancer Manage. Res. 2013, 5, 301-313 10.2147/CMAR.S36105
174. Guzmán, M. Cannabinoids: Potential Anticancer Agents Nat. Rev. Cancer 2003, 3 (10) 745-755 10.1038/nrc1188
175. Qamri, Z.; Preet, A.; Nasser, M. W.; Bass, C. E.; Leone, G.; Barsky, S. H.; Ganju, R. K. Synthetic Cannabinoid Receptor Agonists Inhibit Tumor Growth and Metastasis of Breast Cancer Mol. Cancer Ther. 2009, 8 (11) 3117-3129 10.1158/1535-7163.MCT-09-0448
176. Sarfaraz, S.; Adhami, V. M.; Syed, D. N.; Afaq, F.; Mukhtar, H. Cannabinoids for Cancer Treatment: Progress and Promise Cancer Res. 2008, 68 (2) 339-342 10.1158/0008-5472.CAN-07-2785
177. Hermanson, D. J.; Marnett, L. J. Cannabinoids, Endocannabinoids, and Cancer Cancer Metastasis Rev. 2011, 30 (3-4) 599-612 10.1007/s10555-011-9318-8
178. Galve-Roperh, I.; Sánchez, C.; Cortés, M. L.; Gómez del Pulgar, T.; Izquierdo, M.; Guzmán, M. Anti-Tumoral Action of Cannabinoids: Involvement of Sustained Ceramide Accumulation and Extracellular Signal-Regulated Kinase Activation Nat. Med. 2000, 6 (3) 313-319 10.1038/73171
179. Hall, W.; Christie, M.; Currow, D. Cannabinoids and Cancer: Causation, Remediation, and Palliation Lancet Oncol. 2005, 6 (1) 35-42 10.1016/S1470-2045(05)70024-3
180. Ayakannu, T.; Taylor, A. H.; Marczylo, T. H.; Willets, J. M.; Konje, J. C. The Endocannabinoid System and Sex Steroid Hormone-Dependent Cancers Int. J. Endocrinol. 2013, 2013, 1-14 10.1155/2013/259676
181. Portella, G.; Laezza, C.; Laccetti, P.; De Petrocellis, L.; Di Marzo, V.; Bifulco, M. Inhibitory Effects of Cannabinoid CB1 Receptor Stimulation on Tumor Growth and Metastatic Spreading: Actions on Signals Involved in Angiogenesis and Metastasis FASEB J. 2003, 17 (12) 1771-1773 10.1096/fj.02-1129fje
182. Blázquez, C.; Casanova, M. L.; Planas, A.; Gómez Del Pulgar, T.; Villanueva, C.; Fernández-Acenfnof;ero, M. J.; Aragonés, J.; Huffman, J. W.; Jorcano, J. L.; Guzmán, M. Inhibition of Tumor Angiogenesis by Cannabinoids FASEB J. 2003, 17 (3) 529-531 10.1096/fj.02-0795fje
183. Casanova, M. L.; Blázquez, C.; Martínez-Palacio, J.; Villanueva, C.; Fernández-Acenfnof;ero, M. J.; Huffman, J. W.; Jorcano, J. L.; Guzmán, M. Inhibition of Skin Tumor Growth and Angiogenesis in Vivo by Activation of Cannabinoid Receptors J. Clin. Invest. 2003, 111 (1) 43-50 10.1172/JCI200316116
184. Islam, T. C.; Asplund, A. C.; Lindvall, J. M.; Nygren, L.; Liden, J.; Kimby, E.; Christensson, B.; Smith, C. I. E.; Sander, B. High Level of Cannabinoid Receptor 1, Absence of Regulator of G Protein Signalling 13 and Differential Expression of Cyclin D1 in Mantle Cell Lymphoma Leukemia 2003, 17 (9) 1880-1890 10.1038/sj.leu.2403057
185. Caffarel, M. M.; Sarrió, D.; Palacios, J.; Guzmán, M.; Sánchez, C. Delta9-Tetrahydrocannabinol Inhibits Cell Cycle Progression in Human Breast Cancer Cells through Cdc2 Regulation Cancer Res. 2006, 66 (13) 6615-6621 10.1158/0008-5472.CAN-05-4566
186. Alberich Jordà, M.; Rayman, N.; Tas, M.; Verbakel, S. E.; Battista, N.; van Lom, K.; Löwenberg, B.; Maccarrone, M.; Delwel, R. The Peripheral Cannabinoid Receptor Cb2, Frequently Expressed on AML Blasts, Either Induces a Neutrophilic Differentiation Block or Confers Abnormal Migration Properties in a Ligand-Dependent Manner Blood 2004, 104 (2) 526-534 10.1182/blood-2003-12-4357
187. Sánchez, C.; de Ceballos, M. L.; Gomez del Pulgar, T.; Rueda, D.; Corbacho, C.; Velasco, G.; Galve-Roperh, I.; Huffman, J. W.; Ramón y Cajal, S.; Guzmán, M. Inhibition of Glioma Growth in Vivo by Selective Activation of the CB(2) Cannabinoid Receptor Cancer Res. 2001, 61 (15) 5784-5789
188. Schley, M.; Ständer, S.; Kerner, J.; Vajkoczy, P.; Schüpfer, G.; Dusch, M.; Schmelz, M.; Konrad, C. Predominant CB2 Receptor Expression in Endothelial Cells of Glioblastoma in Humans Brain Res. Bull. 2009, 79 (5) 333-337 10.1016/j.brainresbull.2009.01.011
189. Solinas, M.; Massi, P.; Cantelmo, A. R.; Cattaneo, M. G.; Cammarota, R.; Bartolini, D.; Cinquina, V.; Valenti, M.; Vicentini, L. M.; Noonan, D. M. et al. Cannabidiol Inhibits Angiogenesis by Multiple Mechanisms Br. J. Pharmacol. 2012, 167 (6) 1218-1231 10.1111/j.1476-5381.2012.02050.x
190. Do, Y.; McKallip, R. J.; Nagarkatti, M.; Nagarkatti, P. S. Activation through Cannabinoid Receptors 1 and 2 on Dendritic Cells Triggers NF-kappaB-Dependent Apoptosis: Novel Role for Endogenous and Exogenous Cannabinoids in Immunoregulation J. Immunol. 2004, 173 (4) 2373-2382 10.4049/jimmunol.173.4.2373
191. De Filippis, D.; Russo, A.; De Stefano, D.; Maiuri, M. C.; Esposito, G.; Cinelli, M. P.; Pietropaolo, C.; Carnuccio, R.; Russo, G.; Iuvone, T. Local Administration of WIN 55,212-2 Reduces Chronic Granuloma-Associated Angiogenesis in Rat by Inhibiting NF-kappaB Activation J. Mol. Med. (Heidelberg, Ger.) 2007, 85 (6) 635-645 10.1007/s00109-007-0188-z
192. Blázquez, C.; Carracedo, A.; Barrado, L.; Real, P. J.; Fernández-Luna, J. L.; Velasco, G.; Malumbres, M.; Guzmán, M. Cannabinoid Receptors as Novel Targets for the Treatment of Melanoma FASEB J. 2006, 20 (14) 2633-2635 10.1096/fj.06-6638fje
193. Bellacosa, A.; Kumar, C. C.; Di Cristofano, A.; Testa, J. R. Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting Adv. Cancer Res. 2005, 94, 29-86 10.1016/S0065-230X(05)94002-5
194. Wang, D.; Wang, H.; Ning, W.; Backlund, M. G.; Dey, S. K.; DuBois, R. N. Loss of Cannabinoid Receptor 1 Accelerates Intestinal Tumor Growth Cancer Res. 2008, 68 (15) 6468-6476 10.1158/0008-5472.CAN-08-0896
195. Romano, B.; Borrelli, F.; Pagano, E.; Cascio, M. G.; Pertwee, R. G.; Izzo, A. A. Inhibition of Colon Carcinogenesis by a Standardized Cannabis Sativa Extract with High Content of Cannabidiol Phytomedicine 2014, 21 (5) 631-639 10.1016/j.phymed.2013.11.006
196. Izzo, A. The Cannabinoid CB(2) Receptor: A Good Friend in the Gut Neurogastroenterol. Motil. 2007, 19 (9) 704-708 10.1111/j.1365-2982.2007.00977.x
197. Pérez-Gómez, E.; Andradas, C.; Blasco-Benito, S.; Caffarel, M. M.; García-Taboada, E.; Villa-Morales, M.; Moreno, E.; Hamann, S.; Martín-Villar, E.; Flores, J. M. et al. Role of Cannabinoid Receptor CB2 in HER2 Pro-Oncogenic Signaling in Breast Cancer J. Natl. Cancer Inst. 2015, 107 (6) djv077 10.1093/jnci/djv077
198. Guindon, J.; Hohmann, A. G. The Endocannabinoid System and Cancer: Therapeutic Implication Br. J. Pharmacol. 2011, 163 (7) 1447-1463 10.1111/j.1476-5381.2011.01327.x
199. Orellana-Serradell, O.; Poblete, C. E.; Sanchez, C.; Castellón, E. A.; Gallegos, I.; Huidobro, C.; Llanos, M. N.; Contreras, H. R. Proapoptotic Effect of Endocannabinoids in Prostate Cancer Cells Oncol. Rep. 2015, 33 (4) 1599-1608 10.3892/or.2015.3746
200. Gilron, I.; Baron, R.; Jensen, T. Neuropathic Pain: Principles of Diagnosis and Treatment Mayo Clin. Proc. 2015, 90 (4) 532-545 10.1016/j.mayocp.2015.01.018
201. Tauben, D. Nonopioid Medications for Pain Phys. Med. Rehabil. Clin. N. Am. 2015, 26 (2) 219-248 10.1016/j.pmr.2015.01.005
202. Woodhams, S. G.; Sagar, D. R.; Burston, J. J.; Chapman, V. The Role of the Endocannabinoid System in Pain Handb. Exp. Pharmacol. 2015, 227, 119-143 10.1007/978-3-662-46450-2
203. Devesa, I.; Ferrer-Montiel, A. Neurotrophins, Endocannabinoids and Thermo-Transient Receptor Potential: A Threesome in Pain Signalling Eur. J. Neurosci. 2014, 39 (3) 353-362 10.1111/ejn.12455
204. Hill, K. P. Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems JAMA 2015, 313 (24) 2474-2483 10.1001/jama.2015.6199
205. Whiting, P. F.; Wolff, R. F.; Deshpande, S.; Di Nisio, M.; Duffy, S.; Hernandez, A. V.; Keurentjes, J. C.; Lang, S.; Misso, K.; Ryder, S. et al. Cannabinoids for Medical Use JAMA 2015, 313 (24) 2456-2473 10.1001/jama.2015.6358
206. Gilron, I.; Dickenson, A. H. Emerging Drugs for Neuropathic Pain Expert Opin. Emerging Drugs 2014, 19 (3) 329-341 10.1517/14728214.2014.915025
207. Lucchesi, V.; Parkkari, T.; Savinainen, J. R.; Malfitano, A. M.; Allarà, M.; Bertini, S.; Castelli, F.; Del Carlo, S.; Laezza, C.; Ligresti, A. et al. 1,2-Dihydro-2-Oxopyridine-3-Carboxamides: The C-5 Substituent Is Responsible for Functionality Switch at CB2 Cannabinoid Receptor Eur. J. Med. Chem. 2014, 74, 524-532 10.1016/j.ejmech.2013.10.070
208. Davis, M. P. Cannabinoids in Pain Management: CB1, CB2 and Non-Classic Receptor Ligands Expert Opin. Invest. Drugs 2014, 23 (8) 1123-1140 10.1517/13543784.2014.918603
209. Vincenzi, F.; Targa, M.; Corciulo, C.; Tabrizi, M. A.; Merighi, S.; Gessi, S.; Saponaro, G.; Baraldi, P. G.; Borea, P. A.; Varani, K. Antinociceptive Effects of the Selective CB2 Agonist MT178 in Inflammatory and Chronic Rodent Pain Models Pain 2013, 154 (6) 864-873 10.1016/j.pain.2013.02.007
210. Ikeda, H.; Ikegami, M.; Kai, M.; Ohsawa, M.; Kamei, J. Activation of Spinal Cannabinoid CB2 Receptors Inhibits Neuropathic Pain in Streptozotocin-Induced Diabetic Mice Neuroscience 2013, 250, 446-454 10.1016/j.neuroscience.2013.07.040
211. Grim, T. W.; Ghosh, S.; Hsu, K.-L.; Cravatt, B. F.; Kinsey, S. G.; Lichtman, A. H. Combined Inhibition of FAAH and COX Produces Enhanced Anti-Allodynic Effects in Mouse Neuropathic and Inflammatory Pain Models Pharmacol., Biochem. Behav. 2014, 124, 405-411 10.1016/j.pbb.2014.07.008
212. Deng, L.; Guindon, J.; Cornett, B. L.; Makriyannis, A.; Mackie, K.; Hohmann, A. G. Chronic Cannabinoid Receptor 2 Activation Reverses Paclitaxel Neuropathy without Tolerance or Cannabinoid Receptor 1-Dependent Withdrawal Biol. Psychiatry 2015, 77 (5) 475-487 10.1016/j.biopsych.2014.04.009
213. Chen, X.; Zheng, C.; Qian, J.; Sutton, S. W.; Wang, Z.; Lv, J.; Liu, C.; Zhou, N. Involvement of B-Arrestin-2 and Clathrin in Agonist-Mediated Internalization of the Human Cannabinoid CB2 Receptor Curr. Mol. Pharmacol. 2014, 7 (1) 67-80 10.2174/1874467207666140714115824
214. Petrov, R. R.; Knight, L.; Chen, S.-R.; Wager-Miller, J.; McDaniel, S. W.; Diaz, F.; Barth, F.; Pan, H.-L.; Mackie, K.; Cavasotto, C. N. et al. Mastering Tricyclic Ring Systems for Desirable Functional Cannabinoid Activity Eur. J. Med. Chem. 2013, 69, 881-907 10.1016/j.ejmech.2013.09.038
215. Jean-Gilles, L.; Braitch, M.; Latif, M. L.; Aram, J.; Fahey, A. J.; Edwards, L. J.; Robins, R. A.; Tanasescu, R.; Tighe, P. J.; Gran, B. et al. Effects of pro-Inflammatory Cytokines on Cannabinoid CB1 and CB2 Receptors in Immune Cells Acta Physiol. 2015, 214 (1) 63-74 10.1111/apha.12474
216. Gui, H.; Tong, Q.; Qu, W.; Mao, C.-M.; Dai, S.-M. The Endocannabinoid System and Its Therapeutic Implications in Rheumatoid Arthritis Int. Immunopharmacol. 2015, 26 (1) 86-91 10.1016/j.intimp.2015.03.006
217. Han, S.; Thatte, J.; Buzard, D. J.; Jones, R. M. Therapeutic Utility of Cannabinoid Receptor Type 2 (CB(2)) Selective Agonists J. Med. Chem. 2013, 56 (21) 8224-8256 10.1021/jm4005626
218. Gilron, I.; Baron, R.; Jensen, T. Neuropathic Pain: Principles of Diagnosis and Treatment Mayo Clin. Proc. 2015, 90 (4) 532-545 10.1016/j.mayocp.2015.01.018
219. Tauben, D. Nonopioid Medications for Pain Phys. Med. Rehabil. Clin. N. Am. 2015, 26 (2) 219-248 10.1016/j.pmr.2015.01.005
220. Moris, D.; Georgopoulos, S.; Felekouras, E.; Patsouris, E.; Theocharis, S. The Effect of Endocannabinoid System in Ischemia-Reperfusion Injury: A Friend or a Foe? Expert Opin. Ther. Targets 2015, 1-15 10.1517/14728222.2015.1043268
221. Malik, Z.; Baik, D.; Schey, R. The Role of Cannabinoids in Regulation of Nausea and Vomiting, and Visceral Pain Curr. Gastroenterol. Rep. 2015, 17 (2) 429 10.1007/s11894-015-0429-1
222. Sun, Y.-X.; Xu, A.-H.; Yang, Y.; Zhang, J.-X.; Yu, A.-W. Activation of Cannabinoid Receptor 2 Enhances Osteogenic Differentiation of Bone Marrow Derived Mesenchymal Stem Cells BioMed Res. Int. 2015, 2015, 874982 10.1155/2015/874982
223. Rossi, F.; Bellini, G.; Tortora, C.; Bernardo, M. E.; Luongo, L.; Conforti, A.; Starc, N.; Manzo, I.; Nobili, B.; Locatelli, F. et al. CB2 and TRPV1 Receptors Oppositely Modulate in Vitro Human Osteoblast Activity Pharmacol. Res. 2015, 99, 194 10.1016/j.phrs.2015.06.010
224. Zofková, I.; Matucha, P. New Insights into the Physiology of Bone Regulation: The Role of Neurohormones Physiol. Res. 2014, 63 (4) 421-427
225. Huffman, J. W.; Yu, S.; Showalter, V.; Abood, M. E.; Wiley, J. L.; Compton, D. R.; Martin, B. R.; Bramblett, R. D.; Reggio, P. H. Synthesis and Pharmacology of a Very Potent Cannabinoid Lacking a Phenolic Hydroxyl with High Affinity for the CB2 Receptor J. Med. Chem. 1996, 39 (20) 3875-3877 10.1021/jm960394y
226. Elmes, S. J. R.; Jhaveri, M. D.; Smart, D.; Kendall, D. A.; Chapman, V. Cannabinoid CB2 Receptor Activation Inhibits Mechanically Evoked Responses of Wide Dynamic Range Dorsal Horn Neurons in Naïve Rats and in Rat Models of Inflammatory and Neuropathic Pain Eur. J. Neurosci. 2004, 20 (9) 2311-2320 10.1111/j.1460-9568.2004.03690.x
227. Elmes, S. J. R.; Winyard, L. A.; Medhurst, S. J.; Clayton, N. M.; Wilson, A. W.; Kendall, D. A.; Chapman, V. Activation of CB1 and CB2 Receptors Attenuates the Induction and Maintenance of Inflammatory Pain in the Rat Pain 2005, 118 (3) 327-335 10.1016/j.pain.2005.09.005
228. Michler, T.; Storr, M.; Kramer, J.; Ochs, S.; Malo, A.; Reu, S.; Göke, B.; Schäfer, C. Activation of Cannabinoid Receptor 2 Reduces Inflammation in Acute Experimental Pancreatitis via Intra-Acinar Activation of p38 and MK2-Dependent Mechanisms Am. J. Physiol. Gastrointest. Liver Physiol. 2013, 304 (2) G181-G192 10.1152/ajpgi.00133.2012
229. Ramirez, S. H.; Haskó, J.; Skuba, A.; Fan, S.; Dykstra, H.; McCormick, R.; Reichenbach, N.; Krizbai, I.; Mahadevan, A.; Zhang, M. et al. Activation of Cannabinoid Receptor 2 Attenuates Leukocyte-Endothelial Cell Interactions and Blood-Brain Barrier Dysfunction under Inflammatory Conditions J. Neurosci. 2012, 32 (12) 4004-4016 10.1523/JNEUROSCI.4628-11.2012
230. Li, Q.; Wang, F.; Zhang, Y.-M.; Zhou, J.-J.; Zhang, Y. Activation of Cannabinoid Type 2 Receptor by JWH133 Protects Heart against Ischemia/reperfusion-Induced Apoptosis Cell. Physiol. Biochem. 2013, 31 (4-5) 693-702 10.1159/000350088
231. Hanus, A.; Tchilibon, S.; Shiloah, S.; Goldenberg, D.; Horowitz, M.; Pertwee, R. G.; Ross, R. A.; Mechoulam, R.; Fride, E. L.; Breuer HU-308: A Specific Agonist for CB2, a Peripheral Cannabinoid Receptor Proc. Natl. Acad. Sci. U. S. A. 1999, 96 (25) 14228-14233 10.1073/pnas.96.25.14228
232. LaBuda, C. J.; Koblish, M.; Little, P. J. Cannabinoid CB2 Receptor Agonist Activity in the Hindpaw Incision Model of Postoperative Pain Eur. J. Pharmacol. 2005, 527 (1-3) 172-174 10.1016/j.ejphar.2005.10.020
233. Malan, T. P.; Ibrahim, M. M.; Deng, H.; Liu, Q.; Mata, H. P.; Vanderah, T.; Porreca, F.; Makriyannis, A. CB2 Cannabinoid Receptor-Mediated Peripheral Antinociception Pain 2001, 93 (3) 239-245 10.1016/S0304-3959(01)00321-9
234. Ibrahim, M. M.; Deng, H.; Zvonok, A.; Cockayne, D. A.; Kwan, J.; Mata, H. P.; Vanderah, T. W.; Lai, J.; Porreca, F.; Makriyannis, A. et al. Activation of CB2 Cannabinoid Receptors by AM1241 Inhibits Experimental Neuropathic Pain: Pain Inhibition by Receptors Not Present in the CNS Proc. Natl. Acad. Sci. U. S. A. 2003, 100 (18) 10529-10533 10.1073/pnas.1834309100
235. Wilkerson, J. L.; Gentry, K. R.; Dengler, E. C.; Wallace, J. A.; Kerwin, A. A.; Kuhn, M. N.; Zvonok, A. M.; Thakur, G. A.; Makriyannis, A.; Milligan, E. D. Immunofluorescent Spectral Analysis Reveals the Intrathecal Cannabinoid Agonist, AM1241, Produces Spinal Anti-Inflammatory Cytokine Responses in Neuropathic Rats Exhibiting Relief from Allodynia Brain Behav. 2012, 2 (2) 155-177 10.1002/brb3.44
236. Giblin, G. M.; O'Shaughnessy, C. T.; Naylor, A.; Mitchell, W. L.; Eatherton, A. J.; Slingsby, B. P.; Rawlings, D. A.; Goldsmith, P.; Brown, A. J.; Haslam, C. P. et al. Discovery of 2-[(2,4-Dichlorophenyl)amino]-N-[(tetrahydro- 2H-Pyran-4-Yl)methyl]-4-(trifluoromethyl)- 5-Pyrimidinecarboxamide, a Selective CB2 Receptor Agonist for the Treatment of Inflammatory Pain J. Med. Chem. 2007, 50 (11) 2597-2600 10.1021/jm061195+
237. Mitchell, W. L.; Giblin, G. M.; Naylor, A.; Eatherton, A. J.; Slingsby, B. P.; Rawlings, A. D.; Jandu, K. S.; Haslam, C. P.; Brown, A. J.; Goldsmith, P. et al. Pyridine-3-Carboxamides as Novel CB(2) Agonists for Analgesia Bioorg. Med. Chem. Lett. 2009, 19 (1) 259-263 10.1016/j.bmcl.2008.10.118
238. Zindell, R.; Riether, D.; Bosanac, T.; Berry, A.; Gemkow, M. J.; Ebneth, A.; Lobbe, S.; Raymond, E. L.; Thome, D.; Shih, D. T. et al. Morpholine Containing CB2 Selective Agonists Bioorg. Med. Chem. Lett. 2009, 19 (6) 1604-1609 10.1016/j.bmcl.2009.02.033
239. Gleave, R. J.; Beswick, P. J.; Brown, A. J.; Giblin, G. M. P.; Haslam, C. P.; Livermore, D.; Moses, A.; Nicholson, N. H.; Page, L. W.; Slingsby, B. et al. 2-Amino-5-Aryl-Pyridines as Selective CB2 Agonists: Synthesis and Investigation of Structure-Activity Relationships Bioorg. Med. Chem. Lett. 2009, 19 (23) 6578-6581 10.1016/j.bmcl.2009.10.041
240. Gleave, R. J.; Beswick, P. J.; Brown, A. J.; Giblin, G. M.; Goldsmith, P.; Haslam, C. P.; Mitchell, W. L.; Nicholson, N. H.; Page, L. W.; Patel, S. et al. Synthesis and Evaluation of 3-Amino-6-Aryl-Pyridazines as Selective CB(2) Agonists for the Treatment of Inflammatory Pain Bioorg. Med. Chem. Lett. 2010, 20 (2) 465-468 10.1016/j.bmcl.2009.11.117
241. Odan, M.; Ishizuka, N.; Hiramatsu, Y.; Inagaki, M.; Hashizume, H.; Fujii, Y.; Mitsumori, S.; Morioka, Y.; Soga, M.; Deguchi, M. et al. Discovery of S-777469: An Orally Available CB2 Agonist as an Antipruritic Agent Bioorg. Med. Chem. Lett. 2012, 22 (8) 2803-2806 10.1016/j.bmcl.2012.02.072
242. Van der Stelt, M.; Cals, J.; Broeders-Josten, S.; Cottney, J.; van der Doelen, A. A.; Hermkens, M.; de Kimpe, V.; King, A.; Klomp, J.; Oosterom, J. et al. Discovery and Optimization of 1-(4-(pyridin-2-Yl)benzyl)imidazolidine-2,4-Dione Derivatives as a Novel Class of Selective Cannabinoid CB2 Receptor Agonists J. Med. Chem. 2011, 54 (20) 7350-7362 10.1021/jm200916p
243. Chu, G. H.; Saeui, C. T.; Worm, K.; Weaver, D. G.; Goodman, A. J.; Broadrup, R. L.; Cassel, J. A.; DeHaven, R. N.; LaBuda, C. J.; Koblish, M. et al. Novel Pyridine Derivatives as Potent and Selective CB2 Cannabinoid Receptor Agonists Bioorg. Med. Chem. Lett. 2009, 19 (20) 5931-5935 10.1016/j.bmcl.2009.08.063
244. Gavelle, O.; Grether, U.; Kimbara, A.; Nettekoven, M.; Roever, S.; Rogers-Evans, M.; Rombrach, D.; Schulz-Gasch, T. Novel Pyridine Derivatives. WO2014154612, 2014.
245. Worm, K.; Zhou, Q. J.; Saeui, C. T.; Green, R. C.; Cassel, J. A.; Stabley, G. J.; DeHaven, R. N.; Conway-James, N.; LaBuda, C. J.; Koblish, M. et al. Sulfamoyl Benzamides as Novel CB2 Cannabinoid Receptor Ligands Bioorg. Med. Chem. Lett. 2008, 18 (9) 2830-2835 10.1016/j.bmcl.2008.04.006
246. Goodman, A. J.; Ajello, C. W.; Worm, K.; Le Bourdonnec, B.; Savolainen, M. A.; O'Hare, H.; Cassel, J. A.; Stabley, G. J.; DeHaven, R. N.; LaBuda, C. J. et al. CB(2) Selective Sulfamoyl Benzamides: Optimization of the Amide Functionality Bioorg. Med. Chem. Lett. 2009, 19 (2) 309-313 10.1016/j.bmcl.2008.11.091
247. Sellitto, I.; Le Bourdonnec, B.; Worm, K.; Goodman, A.; Savolainen, M. A.; Chu, G. H.; Ajello, C. W.; Saeui, C. T.; Leister, L. K.; Cassel, J. A. et al. Novel Sulfamoyl Benzamides as Selective CB2 Agonists with Improved in Vitro Metabolic Stability Bioorg. Med. Chem. Lett. 2010, 20 (1) 387-391 10.1016/j.bmcl.2009.10.062
248. Ohta, H.; Ishizaka, T.; Tatsuzuki, M.; Yoshinaga, M.; Iida, I.; Tomishima, Y.; Toda, Y.; Saito, S. N-Alkylidenearylcarboxamides as New Potent and Selective CB2 Cannabinoid Receptor Agonists with Good Oral Bioavailability Bioorg. Med. Chem. Lett. 2007, 17 (22) 6299-6304 10.1016/j.bmcl.2007.09.004
249. Ohta, H.; Ishizaka, T.; Tatsuzuki, M.; Yoshinaga, M.; Iida, I.; Yamaguchi, T.; Tomishima, Y.; Futaki, N.; Todac, Y.; Saito, S. Imine Derivatives as New Potent and Selective CB2 Cannabinoid Receptor Agonists with an Analgesic Action Bioorg. Med. Chem. 2008, 16 (3) 1111-1124 10.1016/j.bmc.2007.10.087
250. Cheng, Y.; Albrech, B. K.; Brown, J.; Buchanan, J. L.; Buckner, W. H.; DiMauro, E. F.; Emkey, R.; Fremeau, R. T.; Harrnange, J. C.; Hoffman, B. J. et al. Discovery and Optimization of a Novel Series of N-Arylamide Oxadiazoles as Potent, Highly Selective and Orally Bioavailable Cannabinoid Receptor 2 (CB(2)) Agonists J. Med. Chem. 2008, 51 (16) 5019-5034 10.1021/jm800463f
251. DiMauro, E. F.; Buchanan, J. L.; Cheng, A.; Emkey, R.; Hitchcock, S. A.; Huang, L.; Huang, M. Y.; Janosky, B.; Lee, J. H.; Li, X. et al. Structural Modifications of N-Arylamide Oxadiazoles: Identification of N-Arylpiperidine Oxadiazoles as Potent and Selective Agonists of CB(2) Bioorg. Med. Chem. Lett. 2008, 18 (15) 4267-4274 10.1016/j.bmcl.2008.06.096
252. Marx, I. E.; DiMauro, E. F.; Cheng, A.; Emkey, R.; Hitchcock, S. A.; Huang, L. Y.; Huang, M. Y.; Human, J.; Lee, J. H.; Li, X. W. et al. Discovery of Alpha-Amidosulfones as Potent and Selective Agonists of CB(2): Synthesis, SAR, and Pharmacokinetic Properties Bioorg. Med. Chem. Lett. 2009, 19 (1) 31-35 10.1016/j.bmcl.2008.11.026
253. Yang, S.-W.; Smotryski, J.; Matasi, J.; Ho, G.; Tulshian, D.; Greenlee, W. J.; Brusa, R.; Beltramo, M.; Cox, K. Structure-Activity Relationships of 2,4-Diphenyl-1H-Imidazole Analogs as CB2 Receptor Agonists for the Treatment of Chronic Pain Bioorg. Med. Chem. Lett. 2011, 21 (1) 182-185 10.1016/j.bmcl.2010.11.044
254. Page, D.; Balaux, E.; Boisvert, L.; Liu, Z.; Milburn, C.; Tremblay, M.; Wei, Z.; Woo, S.; Luo, X.; Cheng, Y. X. et al. Novel Benzimidazole Derivatives as Selective CB2 Agonists Bioorg. Med. Chem. Lett. 2008, 18 (13) 3695-3700 10.1016/j.bmcl.2008.05.073
255. Ryckmans, T.; Edwards, M. P.; Horne, V. A.; Correia, A. M.; Owen, D. R.; Thompson, L. R.; Tran, I.; Tutt, M. F.; Young, T. Rapid Assessment of a Novel Series of Selective CB(2) Agonists Using Parallel Synthesis Protocols: A Lipophilic Efficiency (LipE) Analysis Bioorg. Med. Chem. Lett. 2009, 19 (15) 4406-4409 10.1016/j.bmcl.2009.05.062
256. Ando, K.; Iwata, Y. Preparation of Benzoimidazolylsulfone Derivatives for Use as CB2 Receptor Agonists. WO 2010084767, 2010.
257. Iwata, Y.; Ando, K.; Taniguchi, K.; Koba, N.; Sugiura, A.; Sudo, M. Identification of a Highly Potent and Selective CB2 Agonist, RQ-00202730, for the Treatment of Irritable Bowel Syndrome Bioorg. Med. Chem. Lett. 2015, 25 (2) 236-240 10.1016/j.bmcl.2014.11.062
258. Watson, C.; Owen, D. R.; Harding, D.; Kon, I. K.; Lewis, M. L.; Mason, H. J.; Matsumizu, M.; Mukaiyama, T.; Rodriguez-Lens, M.; Shima, A. et al. Optimisation of a Novel Series of Selective CNS Penetrant CB(2) Agonists Bioorg. Med. Chem. Lett. 2011, 21 (14) 4284-4287 10.1016/j.bmcl.2011.05.063
259. Gijsen, H. J.; De Cleyn, M. A.; Surkyn, M.; Van Lommen, G. R.; Verbist, B. M.; Nijsen, M. J.; Meert, T.; Wauwe, J. V.; Aerssens, J. 5-Sulfonyl-Benzimidazoles as Selective CB2 Agonists-Part 2 Bioorg. Med. Chem. Lett. 2012, 22 (1) 547-552 10.1016/j.bmcl.2011.10.091
260. Verbist, B. M.; De Cleyn, M. A.; Surkyn, M.; Fraiponts, E.; Aerssens, J.; Nijsen, M. J.; Gijsen, H. J. 5-Sulfonyl-Benzimidazoles as Selective CB2 Agonists Bioorg. Med. Chem. Lett. 2008, 18 (8) 2574-2579 10.1016/j.bmcl.2008.03.048
261. Yu, X. H.; Cao, C. Q.; Martino, G.; Puma, C.; Morinville, A.; St-Onge, S.; Lessard, E.; Perkins, M. N.; Laird, J. M. A Peripherally Restricted Cannabinoid Receptor Agonist Produces Robust Anti-Nociceptive Effects in Rodent Models of Inflammatory and Neuropathic Pain Pain 2010, 151 (2) 337-344 10.1016/j.pain.2010.07.019
262. Bilodeau, M. T.; Burgey, C. S.; Deng, Z. J.; Hartnett, J. C.; Kett, N. R.; Melamed, J.; Munson, P. M.; Nanda, K. K.; Thompson, W.; Trotter, B. W.; et al., Imidazopyridine Analogs as cb2 Receptor Modulators, Useful in the Treatment of Pain, Respiratory and Non-Respiratory Diseases. WO 2008085302, 2008.
263. Nanda, K. K.; Henze, D. A.; Della Penna, K.; Desai, R.; Leitl, M.; Lemaire, W.; White, R. B.; Yeh, S.; Brouillette, J. N.; Hartman, G. D. et al. Benzimidazole CB2 Agonists: Design, Synthesis and SAR Bioorg. Med. Chem. Lett. 2014, 24 (4) 1218-1221 10.1016/j.bmcl.2013.12.068
264. Trotter, B. W.; Nanda, K. K.; Burgey, C. S.; Potteiger, C. M.; Deng, J. Z.; Green, A. I.; Hartnett, J. C.; Kett, N. R.; Wu, Z.; Henze, D. A. et al. Imidazopyridine CB2 Agonists: Optimization of CB2/CB1 Selectivity and Implications for in Vivo Analgesic Efficacy Bioorg. Med. Chem. Lett. 2011, 21 (8) 2354-2358 10.1016/j.bmcl.2011.02.082
265. Wu, Z.; Green, A. I.; Hartnett, J. C. CB2 Receptor Ligands for the Treatment of Pain. WO 2009025785, 2009.
266. Trotter, B. W.; Nanda, K. K.; Burgey, C. S.; Potteiger, C. M.; Deng, J. Z.; Green, A. I.; Hartnett, J. C.; Kett, N. R.; Wu, Z.; Henze, D. A. et al. Imidazopyridine CB2 Agonists: Optimization of CB2/CB1 Selectivity and Implications for in Vivo Analgesic Efficacy Bioorg. Med. Chem. Lett. 2011, 21 (8) 2354-2358 10.1016/j.bmcl.2011.02.082
267. Hollinshead, S. P.; Astles, P. C.; Chambers, M. G.; Johnson, M. P.; Palmer, J.; Tidwell, M. W. Discovery and Optimization of Novel Purines as Potent and Selective CB2 Agonists Bioorg. Med. Chem. Lett. 2012, 22 (15) 4962-4966 10.1016/j.bmcl.2012.06.035
268. Hollinshead, S. P.; Tidwell, M. W.; Palmer, J.; Guidetti, R.; Sanderson, A.; Johnson, M. P.; Chambers, M. G.; Oskins, J.; Stratford, R.; Astles, P. C. Selective Cannabinoid Receptor Type 2 (CB2) Agonists: Optimization of a Series of Purines Leading to the Identification of a Clinical Candidate for the Treatment of Osteoarthritic Pain J. Med. Chem. 2013, 56 (14) 5722-5733 10.1021/jm400305d
269. Manera, C.; Cascio, M. G.; Benetti, V.; Allara, M.; Tuccinardi, T.; Martinelli, A.; Saccomanni, G.; Vivoli, E.; Ghelardini, C.; Di Marzo, V. et al. New 1,8-Naphthyridine and Quinoline Derivatives as CB2 Selective Agonists Bioorg. Med. Chem. Lett. 2007, 17 (23) 6505-6510 10.1016/j.bmcl.2007.09.089
270. Stern, E.; Muccioli, G. G.; Millet, R.; Goossens, J.-F.; Farce, A.; Chavatte, P.; Poupaert, J. H.; Lambert, D. M.; Depreux, P.; Hénichart, J.-P. Novel 4-Oxo-1,4-Dihydroquinoline-3-Carboxamide Derivatives as New CB2 Cannabinoid Receptors Agonists: Synthesis, Pharmacological Properties and Molecular Modeling J. Med. Chem. 2006, 49 (1) 70-79 10.1021/jm050467q
271. Manera, C.; Saccomanni, G.; Adinolfi, B.; Benetti, V.; Ligresti, A.; Cascio, M. G.; Tuccinardi, T.; Lucchesi, V.; Martinelli, A.; Nieri, P. et al. Rational Design, Synthesis, and Pharmacological Properties of New 1,8-Naphthyridin-2(1H)-on-3-Carboxamide Derivatives as Highly Selective Cannabinoid-2 Receptor Agonists J. Med. Chem. 2009, 52 (12) 3644-3651 10.1021/jm801563d
272. Lucchesi, V.; Hurst, D. P.; Shore, D. M.; Bertini, S.; Ehrmann, B. M.; Allarà, M.; Lawrence, L.; Ligresti, A.; Minutolo, F.; Saccomanni, G. et al. CB2-Selective Cannabinoid Receptor Ligands: Synthesis, Pharmacological Evaluation, and Molecular Modeling Investigation of 1,8-Naphthyridin-2(1H)-One-3-Carboxamides J. Med. Chem. 2014, 57 (21) 8777-8791 10.1021/jm500807e
273. Cianchi, F.; Papucci, L.; Schiavone, N.; Lulli, M.; Magnelli, L.; Vinci, M. C.; Messerini, L.; Manera, C.; Ronconi, E.; Romagnani, P. et al. Cannabinoid Receptor Activation Induces Apoptosis through Tumor Necrosis Factor Alpha-Mediated Ceramide de Novo Synthesis in Colon Cancer Cells Clin. Cancer Res. 2008, 14 (23) 7691-7700 10.1158/1078-0432.CCR-08-0799
274. Pasquini, S.; Botta, L.; Semeraro, T.; Mugnaini, C.; Ligresti, A.; Palazzo, E.; Maione, S.; Di Marzo, V.; Corelli, F. Investigations on the 4-Quinolone-3-Carboxylic Acid Motif. 2. Synthesis and Structure-Activity Relationship of Potent and Selective Cannabinoid-2 Receptor Agonists Endowed with Analgesic Activity in Vivo J. Med. Chem. 2008, 51 (16) 5075-5084 10.1021/jm800552f
275. Pasquini, S.; Ligresti, A.; Mugnaini, C.; Semeraro, T.; Cicione, L.; De Rosa, M.; Guida, F.; Luongo, L.; De Chiaro, M.; Cascio, M. G. et al. Investigations on the 4-Quinolone-3-Carboxylic Acid Motif. 3. Synthesis, Structure-Affinity Relationships, and Pharmacological Characterization of 6-Substituted 4-Quinolone-3-Carboxamides as Highly Selective Cannabinoid-2 Receptor Ligands J. Med. Chem. 2010, 53 (16) 5915-5928 10.1021/jm100123x
276. Pasquini, S.; De Rosa, M.; Pedani, V.; Mugnaini, C.; Guida, F.; Luongo, L.; De Chiaro, M.; Maione, S.; Dragoni, S.; Frosini, M. et al. Investigations on the 4-Quinolone-3-Carboxylic Acid Motif. 4. Identification of New Potent and Selective Ligands for the Cannabinoid Type 2 Receptor with Diverse Substitution Patterns and Antihyperalgesic Effects in Mice J. Med. Chem. 2011, 54 (15) 5444-5453 10.1021/jm200476p
277. El Bakali, J.; Muccioli, G. G.; Renault, N.; Pradal, D.; Body-Malapel, M.; Djouina, M.; Hamtiaux, L.; Andrzejak, V.; Desreumaux, P.; Chavatte, P. et al. 4-Oxo-1,4-Dihydropyridines as Selective CB2 Cannabinoid Receptor Ligands: Structural Insights into the Design of a Novel Inverse Agonist Series J. Med. Chem. 2010, 53 (22) 7918-7931 10.1021/jm100286k
278. 2Cannabinoid Receptor Ligands. Part 2: Discovery of New Agonists Endowed with Protective Effect against Experimental Colitis J. Med. Chem. 2012, 55 (20) 8948-8952 10.1021/jm3008568
279. El Bakali, J.; Muccioli, G. G.; Body-Malapel, M.; Djouina, M.; Klupsch, F.; Ghinet, A.; Barczyk, A.; Renault, N.; Chavatte, P.; Desreumaux, P. et al. Conformational Restriction Leading to a Selective CB2 Cannabinoid Receptor Agonist Orally Active Against Colitis ACS Med. Chem. Lett. 2015, 6 (2) 198-203 10.1021/ml500439x
280. Manley, P. J.; Zartman, A.; Paone, D. V.; Burgey, C. S.; Henze, D. A.; Della Penna, K.; Desai, R.; Leitl, M. D.; Lemaire, W.; White, R. B. et al. Decahydroquinoline Amides as Highly Selective CB2 Agonists: Role of Selectivity on in Vivo Efficacy in a Rodent Model of Analgesia Bioorg. Med. Chem. Lett. 2011, 21 (8) 2359-2364 10.1016/j.bmcl.2011.02.078
281. Cheng, Y.-X.; Pourashraf, M.; Luo, X.; Srivastava, S.; Walpole, C.; Salois, D.; St-Onge, S.; Payza, K.; Lessard, E.; Yu, X. H. et al. Carbolines: A Novel Class of Cannabinoid Agonists with High Aqueous Solubility and Restricted CNS Penetration Bioorg. Med. Chem. Lett. 2012, 22 (4) 1619-1624 10.1016/j.bmcl.2011.12.124
282. Huffman, J. W. The Search for Selective Ligands for the CB2 Receptor Curr. Pharm. Des. 2000, 6 (13) 1323-1337 10.2174/1381612003399347
283. Huffman, J. W.; Zengin, G.; Wu, M.-J.; Lu, J.; Hynd, G.; Bushell, K.; Thompson, A. L. S.; Bushell, S.; Tartal, C.; Hurst, D. P. et al. Structure-Activity Relationships for 1-Alkyl-3-(1-Naphthoyl)indoles at the Cannabinoid CB(1) and CB(2) Receptors: Steric and Electronic Effects of Naphthoyl Substituents. New Highly Selective CB(2) Receptor Agonists Bioorg. Med. Chem. 2005, 13 (1) 89-112 10.1016/j.bmc.2004.09.050
284. Frost, J. M.; Dart, M. J.; Tietje, K. R.; Garrison, T. R.; Grayson, G. K.; Daza, A. V.; El-Kouhen, O. F.; Yao, B. B.; Hsieh, G. C.; Pai, M. et al. Indol-3-Ylcycloalkyl Ketones: Effects of N1 Substituted Indole Side Chain Variations on CB2 Cannabinoid Receptor Activity J. Med. Chem. 2010, 53 (1) 295-315 10.1021/jm901214q
285. Yao, B. B.; Hsieh, G. C.; Frost, J. M.; Fan, Y.; Garrison, T. R.; Daza, A. V.; Grayson, G. K.; Zhu, C. Z.; Pai, M.; Chandran, P. et al. In Vitro and in Vivo Characterization of A-796260: A Selective Cannabinoid CB2 Receptor Agonist Exhibiting Analgesic Activity in Rodent Pain Models Br. J. Pharmacol. 2008, 153 (2) 390-401 10.1038/sj.bjp.0707568
286. Felder, C. C.; Joyce, K. E.; Briley, E. M.; Mansouri, J.; Mackie, K.; Blond, O.; Lai, Y.; Ma, A. L.; Mitchell, R. L. Comparison of the Pharmacology and Signal Transduction of the Human Cannabinoid CB1 and CB2 Receptors Mol. Pharmacol. 1995, 48 (3) 443-450
287. Riether, D.; Wu, L.; Cirillo, P. F.; Berry, A.; Walker, E. R.; Ermann, M.; Noya-Marino, B.; Jenkins, J. E.; Albaugh, D.; Albrecht, C. et al. 1,4-Diazepane Compounds as Potent and Selective CB2 Agonists: Optimization of Metabolic Stability Bioorg. Med. Chem. Lett. 2011, 21 (7) 2011-2016 10.1016/j.bmcl.2011.02.017
288. Zindell, R.; Walker, E. R.; Scott, J.; Amouzegh, P.; Wu, L.; Ermann, M.; Thomson, D.; Fisher, M. B.; Fullenwider, C. L.; Grbic, H. et al. Aryl 1,4-Diazepane Compounds as Potent and Selective CB2 Agonists: Optimization of Drug-like Properties and Target Independent Parameters Bioorg. Med. Chem. Lett. 2011, 21 (14) 4276-4280 10.1016/j.bmcl.2011.05.068
289. Hickey, E. R.; Zindell, R.; Cirillo, P. F.; Wu, L.; Ermann, M.; Berry, A. K.; Thomson, D. S.; Albrecht, C.; Gemkow, M. J.; Riether, D. Selective CB2 Receptor Agonists. Part 1: The Identification of Novel Ligands through Computer-Aided Drug Design (CADD) Approaches Bioorg. Med. Chem. Lett. 2015, 25 (3) 575-580 10.1016/j.bmcl.2014.12.033
290. Riether, D.; Zindell, R.; Wu, L.; Betageri, R.; Jenkins, J. E.; Khor, S.; Berry, A. K.; Hickey, E. R.; Ermann, M.; Albrecht, C. et al. Selective CB2 Receptor Agonists. Part 2: Structure-Activity Relationship Studies and Optimization of Proline-Based Compounds Bioorg. Med. Chem. Lett. 2015, 25 (3) 581-586 10.1016/j.bmcl.2014.12.019
291. Bartolozzi, A.; Cirillo, P. F.; Berry, A. K.; Hickey, E. R.; Thomson, D. S.; Wu, L.; Zindell, R.; Albrecht, C.; Ceci, A.; Gemkow, M. J. et al. Selective CB2 Receptor Agonists. Part 3: The Optimization of a Piperidine-Based Series That Demonstrated Efficacy in an in Vivo Neuropathic Pain Model Bioorg. Med. Chem. Lett. 2015, 25 (3) 587-592 10.1016/j.bmcl.2014.12.031
292. Han, S.; Thoresen, L.; Zhu, X.; Narayanan, S.; Jung, J.-K.; Strah-Pleynet, S.; Decaire, M.; Choi, K.; Xiong, Y.; Yue, D. et al. Discovery of 1a,2,5,5a-Tetrahydro-1H-2,3-Diaza-Cyclopropa[a]pentalen-4-Carboxamides as Potent and Selective CB2 Receptor Agonists Bioorg. Med. Chem. Lett. 2015, 25 (2) 322-326 10.1016/j.bmcl.2014.11.040
293. Tourteau, A.; Andrzejak, V.; Body-Malapel, M.; Lemaire, L.; Lemoine, A.; Mansouri, R.; Djouina, M.; Renault, N.; El Bakali, J.; Desreumaux, P. et al. 3-Carboxamido-5-Aryl-Isoxazoles as New CB2 Agonists for the Treatment of Colitis Bioorg. Med. Chem. 2013, 21 (17) 5383-5394 10.1016/j.bmc.2013.06.010
294. Tourteau, A.; Leleu-Chavain, N.; Body-Malapel, M.; Andrzejak, V.; Barczyk, A.; Djouina, M.; Rigo, B.; Desreumaux, P.; Chavatte, P.; Millet, R. Switching Cannabinoid Response from CB(2) Agonists to FAAH Inhibitors Bioorg. Med. Chem. Lett. 2014, 24 (5) 1322-1326 10.1016/j.bmcl.2014.01.056
295. Yrjölä, S.; Kalliokoski, T.; Laitinen, T.; Poso, A.; Parkkari, T.; Nevalainen, T. Discovery of Novel Cannabinoid Receptor Ligands by a Virtual Screening Approach: Further Development of 2,4,6-Trisubstituted 1,3,5-Triazines as CB2 Agonists Eur. J. Pharm. Sci. 2013, 48 (1-2) 9-20 10.1016/j.ejps.2012.10.020
296. Yrjölä, S.; Sarparanta, M.; Airaksinen, A. J.; Hytti, M.; Kauppinen, A.; Pasonen-Seppänen, S.; Adinolfi, B.; Nieri, P.; Manera, C.; Keinänen, O. et al. Synthesis, in Vitro and in Vivo Evaluation of 1,3,5-Triazines as Cannabinoid CB2 Receptor Agonists Eur. J. Pharm. Sci. 2015, 67, 85-96 10.1016/j.ejps.2014.11.003
297. Horvath, B.; Magid, L.; Mukhopadhyay, P.; Batkai, S.; Rajesh, M.; Park, O.; Tanchian, G.; Gao, R. Y.; Goodfellow, C. E.; Glass, M. et al. A New Cannabinoid CB2 Receptor Agonist HU-910 Attenuates Oxidative Stress, Inflammation and Cell Death Associated with Hepatic Ischaemia/reperfusion Injury Br. J. Pharmacol. 2012, 165 (8) 2462-2478 10.1111/j.1476-5381.2011.01381.x
298. Smoum, R.; Baraghithy, S.; Chourasia, M.; Breuer, A.; Mussai, N.; Attar-Namdar, M.; Kogan, N. M.; Raphael, B.; Bolognini, D.; Cascio, M. G. et al. CB2 Cannabinoid Receptor Agonist Enantiomers HU-433 and HU-308: An Inverse Relationship between Binding Affinity and Biological Potency Proc. Natl. Acad. Sci. U. S. A. 2015, 112, 8774-8779 10.1073/pnas.1503395112
299. Yacovan, A.; Bar-Joseph, A.; Meilin, S.; Amselem, S. Orally Effective Cannabinoid Analogs. WO 2006043260, 2006.
300. Gratzke, C.; Streng, T.; Stief, C. G.; Alroy, I.; Limberg, B. J.; Downs, T. R.; Rosenbaum, J. S.; Hedlund, P.; Andersson, K.-E. Cannabinor, a Selective Cannabinoid-2 Receptor Agonist, Improves Bladder Emptying in Rats with Partial Urethral Obstruction J. Urol. 2011, 185 (2) 731-736 10.1016/j.juro.2010.09.080
301. Gratzke, C.; Streng, T.; Stief, C. G.; Downs, T. R.; Alroy, I.; Rosenbaum, J. S.; Andersson, K.-E.; Hedlund, P. Effects of Cannabinor, a Novel Selective Cannabinoid 2 Receptor Agonist, on Bladder Function in Normal Rats Eur. Urol. 2010, 57 (6) 1093-1100 10.1016/j.eururo.2010.02.027
302. GlaxoSmithKline. Dental Pain 3rd MolarTooth ExtractionGW842166. https://clinicaltrials.gov/ct2/show/NCT00444769. Identifier: NCT00444769.
303. Ostenfeld, T.; Price, J.; Albanese, M.; Bullman, J.; Guillard, F.; Meyer, I.; Leeson, R.; Costantin, C.; Ziviani, L.; Nocini, P. F. et al. A Randomized, Controlled Study to Investigate the Analgesic Efficacy of Single Doses of the Cannabinoid Receptor-2 Agonist GW842166, Ibuprofen or Placebo in Patients with Acute Pain Following Third Molar Tooth Extraction Clin. J. Pain 2011, 27 (8) 668-676 10.1097/AJP.0b013e318219799a
304. Muthuppalaniappan, M.; Balasubramanian, G.; Gullapalli, S.; Joshi, N. K.; Narayanan, S. Novel Cannabinoid Receptor Ligands, Pharmaceutical Compositions Containg Them, and Process for Their Preparation. WO 2006/129178, 2006.
305. Servettaz, A.; Kavian, N.; Nicco, C.; Deveaux, V.; Chéreau, C.; Wang, A.; Zimmer, A.; Lotersztajn, S.; Weill, B.; Batteux, F. Targeting the Cannabinoid Pathway Limits the Development of Fibrosis and Autoimmunity in a Mouse Model of Systemic Sclerosis Am. J. Pathol. 2010, 177 (1) 187-196 10.2353/ajpath.2010.090763
306. Kyowa Hakko Kirin Company. A Comparative Study of KHK6188. https://clinicaltrials.gov/ct2/show/NCT01544296. Identifier: NCT01544296.
307. Rahn, E. J.; Hohmann, A. G. Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside Neurotherapeutics 2009, 6 (4) 713-737 10.1016/j.nurt.2009.08.002
308. McGaraughty, S.; Chu, K. L.; Dart, M. J.; Yao, B. B.; Meyer, M. D. A CB(2) Receptor Agonist, A-836339, Modulates Wide Dynamic Range Neuronal Activity in Neuropathic Rats: Contributions of Spinal and Peripheral CB(2) Receptors Neuroscience 2009, 158 (4) 1652-1661 10.1016/j.neuroscience.2008.11.015
309. Yao, B. B.; Hsieh, G.; Daza, A. V.; Fan, Y.; Grayson, G. K.; Garrison, T. R.; El Kouhen, O.; Hooker, B. A.; Pai, M.; Wensink, E. J. et al. Characterization of a Cannabinoid CB2 Receptor-Selective Agonist, A-836339 [2,2,3,3-Tetramethyl-Cyclopropanecarboxylic Acid [3-(2-Methoxy-Ethyl)-4,5-Dimethyl-3H-Thiazol-(2Z)-Ylidene]-Amide], Using in Vitro Pharmacological Assays, in Vivo Pain Models, and J. Pharmacol. Exp. Ther. 2009, 328 (1) 141-151 10.1124/jpet.108.145011
310. 2Receptor Mediated Analgesic Activity in Chronic Inflammatory and Neuropathic Pain Models in Rats Br. J. Pharmacol. 2011, 162 (2) 428-440 10.1111/j.1476-5381.2010.01046.x
311. Horti, A. G.; Gao, Y.; Ravert, H. T.; Finley, P.; Valentine, H.; Wong, D. F.; Endres, C. J.; Savonenko, A. V.; Dannals, R. F. Synthesis and Biodistribution of [11C]A-836339, a New Potential Radioligand for PET Imaging of Cannabinoid Type 2 Receptors (CB2) Bioorg. Med. Chem. 2010, 18 (14) 5202-5207 10.1016/j.bmc.2010.05.058
312. Eli Lilly and Company. A Study of LY2828360in PatientsWith Osteoarthritic Knee Pain. https://clinicaltrials.gov/ct2/show/NCT01319929. Identifier: NCT01319929.
313. Kalliomäki, J.; Segerdahl, M.; Webster, L.; Reimfelt, A.; Huizar, K.; Annas, P.; Karlsten, R.; Quiding, H. Evaluation of the Analgesic Efficacy of AZD1940, a Novel Cannabinoid Agonist, on Post-Operative Pain after Lower Third Molar Surgical Removal Scand. J. Pain 2013, 4 (1) 17-22 10.1016/j.sjpain.2012.08.004
314. Sekiguchi, K.; Kanazu, T.; Takeuchi, M.; Hasegawa, H.; Yamaguchi, Y. Non-Clinical Evaluation of the Metabolism, Pharmacokinetics and Excretion of S-777469, a New Cannabinoid Receptor 2 Selective Agonist Xenobiotica 2014, 44 (1) 48-58 10.3109/00498254.2013.805853
315. Cara Therapeutics, Inc. A Phase 2 Studyto Evaluate AnalgesicEffect of IV CR845 For Pain Following Bunionectomy Surgery. https://clinicaltrials.gov/ct2/show/NCT01789476. Identifier: NCT01789476.
316. Haruna, T.; Soga, M.; Morioka, Y.; Hikita, I.; Imura, K.; Furue, Y.; Yamamoto, M.; Imura, C.; Ikeda, M.; Yamauchi, A. et al. S-777469, a Novel Cannabinoid Type 2 Receptor Agonist, Suppresses Itch-Associated Scratching Behavior in Rodents through Inhibition of Itch Signal Transmission Pharmacology 2015, 95 (1-2) 95-103 10.1159/000371890
317. Odan, M.; Ishizuka, N.; Hiramatsu, Y.; Inagaki, M.; Hashizume, H.; Fujii, Y.; Mitsumori, S.; Morioka, Y.; Soga, M.; Deguchi, M. et al. Discovery of S-777469: An Orally Available CB2 Agonist as an Antipruritic Agent Bioorg. Med. Chem. Lett. 2012, 22 (8) 2803-2806 10.1016/j.bmcl.2012.02.072
318. Sekiguchi, K.; Fukumura, K.; Hasegawa, H.; Kanazu, T. The Metabolism and Pharmacokinetics of [ 14 C]-S-777469, a New Cannabinoid Receptor 2 Selective Agonist, in Healthy Human Subjects Xenobiotica 2015, 45 (2) 150-157 10.3109/00498254.2014.956158
319. Takai, N.; Tanaka, Y.; Saji, H. Quantification of Small Molecule Drugs in Biological Tissue Sections by Imaging Mass Spectrometry Using Surrogate Tissue-Based Calibration Standards Mass Spectrom. 2014, 3 (1) A0025 10.5702/massspectrometry.A0025
320. Shionogi Inc. A Phase Ib/IIa, Double-Blind,Randomized Studyto Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamicsof S-777469 in Subjects With Atopic Dermatitis. https://clinicaltrials.gov/ct2/show/NCT00697710. Identifier: NCT0069771.
321. Sekiguchi, K.; Kanazu, T.; Takeuchi, M.; Hasegawa, H.; Yamaguchi, Y. Non-Clinical Evaluation of the Metabolism, Pharmacokinetics and Excretion of S-777469, a New Cannabinoid Receptor 2 Selective Agonist Xenobiotica 2014, 44 (1) 48-58 10.3109/00498254.2013.805853